PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(S1) International Patent Classification 6; A61K 51/10, 47/48 // A61K 101:02, 123:00	А3	(31) International Publication Number: WO 99/00150 (43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US (22) International Filing Date: 26 June 1998 (30) Priority Data: 60031,055 27 June 1997 (27.06.97) (71) Applicant (for all designated States except US): R OF THE UNIVERSITY OF CALIFORNIA (ILSN 6007, 300 Lakeside Drive, Oakland, CA 94612-23. (72) Inventor's and (75) Inventor's and (75) Inventor's and (US/US); 1180 Tellem Drive, Pacific Pallisades, (US) (74) Apent: KONDZELLA, Michael, A.; Oppenheimer Donnelly LLP, Suite 3800, 2029 Century Park I Angeles, CA 90067–3024 (US).	26.06.5 [26.06.5] [EGEN]; 22 550 (U: [Illiam, 1] [CA 902	(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, FT, SD. Published With international search report.
	•	

(54) THE: DRUG TARGETING OF A PEPTIDE RADIOPHARMACBUTICAL THROUGH THE PRIMATE BLOOD-BRAIN BARRIER IN VIVO WITH A MONOCLONAL ANTIBODY TO THE HUMAN INSULIN RECEPTOR



(57) Abstract

[125]]—Aβ¹⁻⁴⁰ was mono-biotinylated and conjugated to a blood-brain barrier drug delivery and brain targeting system comprised of a complex of the 33-14 monoclonal antibody (MAb) to the human insulin receptor, which is tagged with streptavidin (SA) to produce a marked increase in rheatus monkey brain uptake of the [125]—bod-Aβ¹⁻⁴⁰ at 3 hours following intravenous injection compared to no measurable brain uptake of [1751]—bio-Aβ¹⁻⁴⁰ in the absence of a BBB drug.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL,	Albania	ES	Spain	LS	Lesotho	sı	Slovenia
AM	Annenia	FI	Finland	LT	Lithoania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Mosaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madegascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Paso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IΕ	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Helarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimhalnes
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	2.,	Lumonowe
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazaketan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE.	Sweden		
RE	Estonia	LR	Liberia	SG	Singapore		

inte Jonal Application N

	PC1/US 98	713398
A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K51/10 A61K47/48 //A61	K101:02,A61K123:00	
According to international Petant Classification (IPC) or to both notional cla	ssification and IPC	
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by class IPC 6 AGIK		
Documentation searched other than minimum documentation to the extent		
Electronic data base consulted during the international search (name of de	ta base and, where practical, search terms used	1)
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category * Citation of document, with indication, where appropriate, of the	hé relavant passages	Relevant to cleim No.
P,X WU, DAFANG ET AL: "Drug targe peptide radiopharmaceutical the primate blood - brain barrier a monoclonal antibody to the h receptor" J. CLIN. INVEST., VOL. 100, NO 1804-1812,1 October 1997, XPOO see the whole document	rough the in vivo with uman insulin . 7. PAGE(S)	1-24
Y Further documents are listed in the continuation of box C.	X Petent family members are listed	In annex.
Special categories of obsid documents: A document diselve the special state of the at which is not contributed to the part of the special state of the special state of the contributed to be of particular relevance. Fe desire document for buildhafe on or atter the international state of the special st	The later decorrect publication enter the con- or probative data and rost no conflict wish child to understand the principle or the child to understand the principle or the control to confidence moves or cannot be considered movel or cannot be considered movel or cannot be considered in the control of the cannot be considered to tracke a time document in combined with one or or the cannot be combined with one or or the cannot be combined with one or or in the all. The control of the cannot be "of-comment entertors of the starting palent."	sory unjuditying the statemed invention ba considered to current is taken alone latimed invention verifice atop when the re other such docu- us to a person skilled family
22 January 1999 forms and mailing address of the ISA European Patient Office, P.B. 58(8 Paterilisan 2 NL - 2200 HV Riempilk Tol. (+31-17) 340-2040, Tx. 31 651 epo nt, Face, (-31-70) 340-3016	03/02/1999 Authorized officer Dullaart, A	

Inti. Jonat Application No PCT/US 98/13398

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category * | Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Υ SAITO Y ET AL: "Vector-mediated delivery 1-24 of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. PROC NATL ACAD SCI U S A, OCT 24 1995, VOL. 92, NO. 22, PAGE(S) 10227-31, XP002090767 see abstract see page 10227, right-hand column - page 10228, left-hand column see figure 1 see paragraph RESULTS WO 88 00834 A (UNIV CALIFORNIA) 1-24 11 February 1988 see examples WO 94 02178 A (US HEALTH) 3 February 1994 1-24 see examples 3,4 γ EP 0 599 303 A (TAKEDA CHEMICAL INDUSTRIES 1-10 LTD) 1 June 1994 see examples Υ PARDRIDGE, WILLIAM M. ET AL: "Human 1-24 insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood - brain barrier in vivo in the primate." PHARMACEUTICAL RESEARCH, 1995, VOL. 12, NO. 6, PAGES 807-816., XP002090768 see abstract see paragraph DISCUSSION see paragraph RESULTS see page 815, left-hand column х MARTEL, C. L. ET AL: "Transport of 1-10. apolipoproteins E and J at the blood -13-18, brain barrier. Relevance to Alzheimer's 21,22 disease" S.T.P. PHARMA SCI., VOL. 7, NO. 1, PAGE(S) 28-36, January 1997 - February 1997, XP002090769 Υ see abstract 1-24 see paragraph II.2 see figures 4.8 see page 35, left-hand column -/--

2

Int Itional Application No PCT/IIS 98/13398

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication where appropriate, of the retevant passages Relevant to claim No. Х PODUSLO, JOSEPH F. ET AL: "Permeability 1-10, and residual plasma volume of human, Dutch 13-18, 21,22 variant, and rat amyloid 8-protein 1-40 at the blood - brain barrier"
NEUROBIOL. DIS., 1997, VOL. 4, NO. 1,
PAGE(S) 27-34, XP002090770 Υ see paragraph DISCUSSION 1-24 Α MARTEL, CYNTHIA L. ET AL: "Blood - brain barrier uptake of the 40 and 42 amino acid 1-24 sequences of circulating Alzheimer's amyloid 8 in guinea pigs" NEUROSCI. LETT., VOL. 206, NO. 2,3, PAGE(S) 157-60,1996, XP002090771 see page 159, right-hand column ZLOKOVIC B V ET AL: "Glycoprotein χ 1-10. 330-megalin: Probable role in receptor 13-18. -mediated transport of apolipoprotein J 21.22 alone and in a complex with Alzheimer disease amyloid beta at the blood - brain and blood-cerebrospinal fluid barriers." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. VOL. 93, NO. 9, 1996, PAGE(S) 4229-4234. XP002090772 Υ see abstract 1-24 see tables 1.2 Y B.V.ZLOKOVIC ET AL.: "Brain uptake of 1-10, circulating apolipoproteins J and E 13-18. complexedto Alzheimer's amyloid 8" 21,22 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 205, no. 2, 15 December 1994, pages -1431-1437, XP002090773 ORLANDO, US see abstract 1 - 24see paragraph RESULTS see floure 2

2

...emational application No.

PCT/US 98/13398

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Int	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	because they relian to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 13-24 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compount/composition.
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box ii	Observations where unity of Invention is lacking (Continuation of Item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1	As all required additional search fees were finely paid by the applicant, this international Search Report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not think playment of term additional fee.
	of any additional fee.
з. 🔲	As only some of the required additional search fees were fixedly paid by the applicant, this informational Search Report covers only those claims for which fees were paid, specifically daims Nos.:
4.	No required additional search fees were smely paid by the applicant. Consequently, this infarmational Search Report is restricted to the invention first membrand in the chaims; it is covered by claims Nos.:
Romark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

International Application No. PCT/US 98 /13398

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 1-23 in part

In view of the large number of compounds, which are defined by the general definition in the claims, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application (see guidelines, Chapter III, paragraph 2.3).

Information on patent family members

In attored Application No

				PC1/US 98/13398			
Patent document cited in search report		Publication date		Patent family member(s)	Publication date		
WO 8800834	A	11-02-1988	US CA DE DE EP JP JP US	4801575 A 1311086 A 3787460 D 3787460 T 0276278 A 2547054 B 1500901 T 4902505 A	31-01-1989 01-12-1992 21-10-1993 17-02-1994 03-08-1988 23-10-1996 30-03-1989 20-02-1990		
W0 9402178	A	03-02-1994	AU CA EP JP	677216 B 4687593 A 2141216 A 0652775 A 7509250 T	17-04-1997 14-02-1994 03-02-1994 17-05-1995 12-10-1995		
EP 0599303	A	01-06-1994	CA JP US	2110086 A 6228199 A 5442043 A	28-05-1994 16-08-1994 15-08-1995		

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Burgau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCI)

(51) International Patent Classification 6: A61K 39/395, C07K 16/00, C12P 21/00	A1	(11) International Publication Number: WO 99/22764 (43) International Publication Date: 14 May 1999 (14.05.99)
(21) International Application Number: PCITUS (22) International Filing Date: 16 October 1998 ((30) Priority Data: 08/962,497 31 October 1997 (31.10.97) (71) Applicant: GENENTECH, INC. [US/US]; 1 DNA W. San Francisco, CA 94080–4990 (US). (72) Inventor: RAIU, T., Shanthar, 1010 Haddoen Dr Mateo, CA 94402 (US). (74) Agentes KUBRIEC, Jeffrey, S. et al.; Genentech, Inc., Way, South San Francisco, CA 94080–4990 (US).	16.10.9 U ay, Sou ive, S:	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD GG, GH, GM, HR, HL, DL, IL, SI, P, KE, KG, KP, KR GE, CG, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN MW, MK, NO, NZ, PL, PT, RO, RU, SD, SE, SO, SI, SS, SI, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARPC patent (AM, AZ, BY, GK, ZK, MD, SK, DC, ZW), Burstein patent (AM, AZ, BY, GK, ZK, MD, SK, BP, T, RR, GB, GR, EI, TI, LU, MC, NL, TY, TS, BD, API patent (BF, BJ, CF, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO). Published
(54) Title: METHODS AND COMPOSITIONS COMPRIS	SING (LYCOPROTEIN GLYCOFORMS

(57) Abstract

This invention relates to novel glycoprotein glycoform preparations comprising the substantially homogeneous glycoprotein glycoforms and combinations thereof. More perticularly the invention relates to glycoprotein preparations comprising a particular Fe glycoforms and excited for producing, detecting, cariching and purifying the glycoforms. The invention further relates to immosploating and especially been computing a FeTZ domain having particular N-linked glycaus. Provided are compositions including pharmaceutical compositions metables of using the proparations as well as articles of manufacture complising the representations.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

Albania	2.5	Spain	LS	Lesotho	SI	Slovenia	
		Pinland	LT	Lithumia	SK		
Austria	FR	France	LU	Luxembourg			
Australia	GA	Gabon	1.V				
		United Kingdom	MC	Monaco			
Bosnia and Herzegovina	GE	Georgia	MD				
Barbados	GH	Ghana	MG				
Belgium	GN	Guinea	MK				
Burkina Faso	GR	Greece					
Bulgaria	HU		MI.				
Benin	IE	Ireland					
Brazil	IL	Teraci					
Belarus	IS	Iceland					
Canada	FF	Iraly					
Central African Republic	JP						
Congo	KE						
Switzerland	KG						
Côte d'Ivoire	KP				711	Zimpaowe	
Camerooo							
China	KR						
Cuba							
Denmark							
Estonia	I.R	Liberia	25	SWeden			
	Amenia Austria Austria Austria Austria Austria Austria Austria Benia and Herzegovina Badgen Benia Badgen Badgen Badgen Benia Benia Benia Benia Benia Benia Benia Benia Central African Republic Congo Switzerland African Republic Congo China C	Amenda 9T	Armenia Fr Falland Armenia Fr Falland Aurelia Fr France Aurelia	Armenia FT Finled LT	Armenis	Amenda	Amenda

METHODS AND COMPOSITIONS COMPRISING GLYCOPROTEIN GLYCOFORMS Background of the Invention

Field of the Invention

This invention relates to glycoprotein glycoforms as well as to novel compositions comprising the glycoprotein composition. More particularly, the invention relates to glycoprotein compositions which comprise glycoproteins such as an immunoglobulin, antibody or immunoadhesin having an immunoglobulin CH2 domain containing particular N-linked glycans. The invention further relates to methods for producing, detecting, enriching and purifying the glycoprotein glycoforms. The invention further relates to pharmaceutical compositions, methods of using the compositions, as well as articles of manufacture comprising the compositions.

Description of Related Disclosures

Differences in glycosylation patterns of recombinantly produced glycoproteins have recently been the topic of much attention in the scientific community as recombinant proteins produced as probable prophylactics and therapeutics approach the clinic. Antibodies or immunoglobulins (Ig) are glycoproteins that play a central role in the humoral immune response. Antibodies and antibody-like molecules such as immunoathesins (U.S. Patent Nos. 5,116,964 and 5,565,335) have been prepared for clinical uses; for example, TNFR-IgG (Ashkenazi et al., (1991) Proc. Natl. Acad. Sci. USA 881-4335-1033, U.S. Patent Nos. 5,610,297 and "Roc4-2081 (TNFR55-1gG1) in the Treatment of Patients with Severe Sepsis and Septic Shock: Preliminary Results' Abruham et al., (1995) in Sec. Intern. Autumnal Them. Meeting on Sepsis, Desuville, Prancey, anti-IL-8 (St John et al., (1993). Chest, 103:932 and International Publication No. WO 95/19813); anti-IER2 (Press et al., (1991), Transplant Ind. 43-7, and Hourmant et al., (1994), Transplantation 38:377-380; anti-IER2 (Carter et al., (1993), 1. Immunol. 151:2623-2632, and International Publication No. WO 95/19813; anti-IER2 (Carter et al., (1992), Proc. Natl. Acad. Sci. USA, 89-4285-4289, and International Publication No. WO 92/208798; anti-I-VEG (Jin Kim et al., (1992) Growth Factors, 7:53-64, and International Publication No. WO 95/19813; and anti-CD20 (Maloney et al., (1994) Blood, 84:2457-2466, Liu et al., (1987) J. Immunol., 130:3521-3526).

Antibodies are glycosylated at conserved positions in their constant regions (Jefferis and Lund (1997)
Chem. Immunol. 65:111-128; Wright and Morrison (1997) TibTECH 15:26-32). The oligosaccharide side
chains of the immunoglobulina affect the protein's function (Boyd et al., (1996) Mol. Immunol. 32:1311-1318;
Wittwer A., and Howard, S.C. (1990) Biochem. 29-4175-4180) and the intramolecular interaction between
portions of the glycoprotein which can affect the conformation and presented three-dimensional surface of the
glycoprotein (defferis and Lund supra; Wyss and Wagner (1996) Curr. Opin. Biotech. 7:409-416; Hart. (1992)
Curr. Opin. Cell Biol., 4:1017-1023; Goochee, et al., (1991) BioTechnology, 9:1347-1355; Parchi, R.B., (1991)
Curr. Opin. Struct. Biol., 1:750-754). Oligosaccharides may also serve to target a given glycoprotein to certain
molecules based upon specific recognition structures. For example, it has been reported that in agalactosylated
lgG, the oligosaccharide moiety 'lipe' out of the inter-CH2 space and terminal N-acetlyglucosamine residues
become available to bind mannose binding protein (Malhorre et al., (1995)) Nature Med. 1:237-243). It has also
been reported that the presence of nonreducing terminal galactose residues in antibody CH2 domains may be
important for binding of lgG to C1 q and Fe receptors (Tauchiye et al., (1995)). Rhem. 16:285-290).

CAMPATH-1H is a recombinant humanized murine monoclonal IgG1 antibody which recognizes the CDw52 antigen of human lymphocytes (Sheeley et al., (1997) Analytical Biochem. 247: 102-110). Removal by glycopeptidase-of the oligosaccharides from CAMPATH-1H produced in chinese hamster ovary (CHO) cells resulted in a complete reduction in complement-mediated cell lysis (CMCL) (Boyd et al., (1996) Mol. Immunol. 5 32:1311-1318); whereas selective removal of sialic acid residues using neuraminidase resulted in no loss of CMCL. CAMPATH-1H treated with β-galactosidase, which is expected to premove terminal galactosyl residues, was found to reduce CMCL by less than one-half (Boyd et al., store).

Since the cell type used for expression of recombinant glycoproteins as potential human therapeutics is rarely the native cell, significant variations in the glycosylation pattern of the glycoproteins can be expected.

10 Tissue plasminogen activator produced in different cell types results in heterogeneously glycosylated molecules (Parekh, et al., (1989) Biochemistry 23: 7644-7662). The same is true for immunoglobulins (Hse, T.A. et al., (1997) J. Biol. Chem. 272:9962-9070).

Much attention has been paid to the factors which affect lycosylation during recombinant protein production such as growth mode (adherent or suspension), media formulation, culture density, oxygenation, plt, 15 purification schemes and the like (Werner, R. and Noe, W. (1993), Drug Res. 43:1134-1249; Hayter at al., (1992) Blotech. and Bloong. 39:327-335; Borys et al., (1994) Blotech and Bloong. 43:505-514; Borys et al., (1993) Blotechnology 11:720-724; Hearing et al., (1989) J. Cell Blol. 108:339-353; Goochee et al., in Frontiers in Bloprocessing II, Todd et al., eds (1992) American Chemical Society pp. 199-246; U.S. Patent No. 5,096,816; Chotigeat, W., (1994) Cytobech 15:217-221). Several groups have investigated the process parameters that affect the production of recombinant proteins, especially the effect of media composition in the production of recombinant proteins (Park et al., (1992) Blotech. Bloong. 40:686-696; Cox and McClure, (1983) In Vitro, 191-6; Mizutani et al., (1992) Biotech. Bloong. 40:686-696; Cox and McClure, (1983) Lymph. 191-6; Mizutani et al., (1992) Biotech and proposed to alker the glycosylation pattern achieved in a particular host organism including introducing or overexpressing certain enzymes involved in oligosaccharide production 25 (U.S. Patent No. 5,07,335 U.S. Patent No. 5,510,261). These schemes are not limited to intracellular methodd (I.S. Patent No. 5,27,802).

While some work has been done to evaluate the structure of the N-linked glycans attached to the heavy chain of clinically relevant antibodies, these studies indicate that various host cells are capable of differential N-glycan processing. Analysis of the produced glycoprotein reveals heterogeneous glycoforms (Wormald et al., 30 (1997) Biochemistry 36:1370-1380). Glycocylation differences in antibodies are generally confined to the constant domain and may influence the antibodies structure (Weitzhandler et al., (1994) J. Pharm. Sci. 83:1760). It is therefore important to ensure that the glycosylation pattern of glycoprotein products produced for clinical use is uniform throughout and between production lots but also that the favorable in yivo properties of the antibodies are at least restained.

Summary of the Invention

35

The present invention provides for compositions comprising glycoprotein agents substantially free of particular glycoforms of the glycoprotein agent. It is a feature of the present invention that when administered to animals including humans, pharmaceutical compositions comprising the novel compositions, in preferred embodiments, advantageously exhibit superior in vivo properties. Thus, the novel compositions may be used

wherever the glycoprotein pharmaceutical agent is used and advantageously provide improved properties as well as increased uniformity between and throughout production lots. The preparations of the invention can be incorporated into solutions, unit dosage forms such as tablets and capsules for oral delivery, as well as into suspensions, ointments and the like, depending on the particular drug or medicament and its target area.

In a particular aspect, the present invention provides novel compositions for glycoprotein pharmaceutical agents, drugs or medicaments wherein the glycoprotein comprises an immunoglobulin CH2 domain and the composition is substantially free of particular glycoforms of the glycoprotein agent. According to a particular aspect of the invention, compositions are provided comprising a glycoprotein having an immunoglobulin CH2 domain wherein the CH2 domain has at least one N-linked oligosaccharide and wherein 10 substantially all of the oligosaccharide is a G-2 oligosaccharide as defined herein. Also provided are compositions comprising a glycoprotein having at least one immunoglobulin CH2 domain wherein the N-linked oligosaccharides of the CH2 domain are substantially of the G2 and G-2 variety. The composition is substantially free of glycoproteins comprising an immunoglobulin CH2 domain wherein the N-linked oligosaccharide is a G1, G0 or G-I oligosaccharide. In preferred aspects the glycoprotein is an antibody and 15 especially a monoclonal antibody. The invention further provides for a method of producing the preparations of the invention.

The invention encompasses pharmaceutical compositions comprising the glycoform preparations of the invention. The compositions are preferably sterile. Where the composition is an aqueous solution, preferably the glycoprotein is soluble. Where the composition is a lyophilized powder, preferably the powder is reconstitutable in an appropriate solvent.

In still another aspect, the invention involves a method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeurically effective dose of the pharmaceutical compositions

It is a further object of the invention to provide the glycoform preparations in an article of manufacture or kit that can be employed for purposes of treating a disease or disorder.

Brief Description of the Drawings

5

20

35

Figure I A, Figure 1B and Figure 1C depict oligosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by capillary electrophoresis with laser-induced fluorescence detection. C2B8 produced in 400L batch-fed culture produced at least four glycoforms of C2B8 (Figure 1A). Figure 1B depicts the same C2B8 preparation treated with β-galactosidase. Figure IC depicts the preparation further treated with N-acetylβ-Dglucosaminosidase A single G-2 glycoform preparation was obtained (G-2).

Figure 2 depicts the binding of C2B8 to C1q using the procedure of Reff et al., (1994) Blood 83:435-445. Both G2 and G-2 preparations bound C1g to a greater extent than control samples exhibiting heterogeneous glycoforms.

Figure 3 denicts the bioactivity of the G2 and G-2 glycoform preparations compared with the preparations having all carbohydrate removed (No) and preparations having only galactose removed (G0) in a rabbit/human complement lysis assay.

Figure 4A and Figure 4B depict oligosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by capillary electrophoresis with laser-induced fluorescence detection. C2B8 produced in 400L batch-fed culture

produced at least three glycoforms of CZB8 (Figure 4A). Figure 4B depicts the same CZB8 preparation after treatment with \$1.4 galactosyltransferase according to the present invention. A single GZ glycoform preparation was obtained.

Figure 5 depicts analysis of an anti-VEGF monoclonal antibody by capillary electrophoresis. It can be 5 seen that anti-VEGF produced in CHO cell culture contained at least three glycoforms forming a heterogeneous composition. The same anti-VEGF after treatment with β-1-4 galactosyltransferase according to the present invention produced a single G2 glycoform.

Figure 6 depicts analysis of an anti-IgE monoclonal antibody by capillary electrophoresis. It can be seen that anti-IgE produced in CHO cell culture contained at least three glycoforms forming a heterogeneous oilgosaccharide population. The same anti-IgE CHO cell composition after treatment with β-1-4 galactosyltransferase according to the present invention produced a single C2 glycoform.

Figure 7 depicts analysis of an anti-HER2 monoclonal antibody by capillary electrophoresis. It can be seen that anti-HER2 produced in CHO cell culture contained at least three glycoforms forming a heterogeneous oilgosaccharide population. The same anti-HER2 CHO composition after treatment with β-1-4 galactosyltransferase according to the present invention produced a single G2 glycoform.

Figure 8 depicts a representative SDS polyacrylamide gel analysis of an anti-CD20 monoclonal antibody under non-reducing conditions. Lane 1 is molecular weight standards, Lane 2 is the G2 glycoform of C288; Lane 3 is the C288 preparation treated with galactosidase to remove galactose residues from the oligoasccharides; Lane 4 is the CHO derived C288 preparation treated with glycopeptidase-F for the removal of intact oligoasccharide; Lane 5 is the C288 antibody from CHO production; Lane 6 is CHO-derived C288 after incubation at 37 C for 28 hours; lane 7 is CHO-derived C288 and BSA. The representative gel shows that the molecular size of the C288 molecule remains intact after treatment with the galactosyltransferase. The G2 glycoform does not disrupt the orimany structure of the antibody.

Figure 9 depicts the same material described above analyzed by polyacrylamide gel electrophoreses
25 under reducing conditions. The C2B8 heavy and light chains remain intact.

Figure 10A and Figure 10B depict far and near UV circular dichroism (CD) spectra of C2B8 antibody from CHO culture and the G2 glycoform. As circular dichroism is sensitive to secondary structure (Provencer and Glockner (1981), Biochem. 20:33-37) it can be concluded that the G2 glycoform has the same secondary structure as C2B8 of heterorenous glycan composition.

30 Figure 11 depicts the bioactivity of the G2 glycoform preparation compared with the heterogeneous composition for C2B8 in a rabbit complement lysis assay.

Figure 12 depicts the correlation of bioactivity and galactose content in the G2 glycoform. The G2 glycoform preparation was at least 1.5 times more active in this assay than that produced under typical cell culture conditions.

Detailed Description of the Preferred Embodiments

Definitions

35

The carbohydrate moieties of the present invention will be described with reference to commonly used nomenclature for the description of oligosaccharides. A review of carbohydrate chemistry which uses this nomenclature is found in Hubbard and Ivatt (1981) Ann. Rev. Biochem. 50:555-583. This nomenclature

includes, for instance, Man, which represents mannose: GlcNAc, which represents 2-N-acetylglucosamine: Gal which represents galactose; Fuc for fucose; and Gle, which represents glucose. Sialic acids are described by the shorthand notation NeuNAc, for 5-N-acetylneuraminic acid, and NeuNGc for 5-glycolylneuraminic acid (J. Biol. Chem, 1982 257:3347; J. Biol. Chem., 1982, 257:3352).

The "CH2" domain of the present invention is meant to describe an immunoglobulin heavy chain constant CH2 domain. In defining an immunoglobulin CH2 domain reference is made to immunoglobulins in general and in particular to the domain structure of immunoglobulins as applied to human IgG1 by Kabat E.A. (1978) Adv. Protein Chem. 32:1-75. Accordingly, immunoglobulins are generally heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each 10 light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has an amino terminal variable domain (VH) followed by carboxy terminal constant domains. Each light chain has a variable N-terminal domain (VL) and a C terminal constant domain; the constant domain of the light chain is aligned with the first constant domain (CH1) of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. According to the domain definition of immunoglobulin polypeptide chains, light (L) chains have two conformationally similar domains VL and CL; and heavy chains have four domains (VH, CH1, CH2, and CH3) each of which has one intrachain disulfide bridge.

Depending on the amino acid sequence of the constant (C) domain of the heavy chains, 20 immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA. 1gD, IgE, IgG, and IgM. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ domains respectively. Sequence studies have shown that the μ chain of IgM contains five domains VH, CHµ1, CHµ2, CHµ3, and CHµ4. The heavy chain of IgE (€) also contains five domains while the heavy chain of IgA (a) has four domains. The immunoglobulin class can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. Of these IgA and IgM are polymeric and each subunit contains two light and two heavy chains, The heavy chain of IgG (y) contains a length of polypeptide chain lying between the CHy1 and CHy2 domains known as the hinge region. The a chain of IgA has a hinge region containing an O-linked glycosylation site and 30 the μ and ε chains do not have a sequence analogous to the hinge region of the γ and α chains, however, they contain a fourth constant domain lacking in the others. The domain composition of immunoglobulin chains can be summarized as follows:

Light Chain $\lambda = V\lambda C\lambda$

5

35

κ = Vκ Cκ

Heavy Chain IgG (y) = VH CHy1, hinge CHy2 CHy3

IgM (u) = VH CHu1 CHu2 CHu3 CHu4 IgA (α) = VH CHα1 hinge CHα2 CHα3 IgE (e) = VH CHe1 CHe2 CHe3 CHe4 IgD (8) = VH CH81 hinge CH82 CH83

A CH2 domain therefore is an immunoglobulin heavy chain constant region domain. According to the present invention, the CH2 domain is preferably the CH2 domain of one of the five immunoglobulins subtypes indicated above. Preferred are mammalian immunoglobulin CH2 domains such as a primate or murine immunoglobulin with the primate and especially human immunoglobulin CH2 domains being preferred. The amino acid sequence of immunoglobulin CH2 domains are known or are generally available to the skilled artisan (Kabat et al. Sequences of rotteins of immunoglobulin CH2 domain within the context of the present invention is a human IgG and preferably from IgG1, IgG2, IgG3, IgG4 and more preferably a human IgG1. Using the numbering system of Edelman, G.M., et al., (1969) Proc. Natl. Acad. Sci. USA 63:78-85 the immunoglobulin CH2 domain preferably begins at amino position equivalent to glutamine 233 of human IgG1 and extends through amino acid equivalent to lysine 340 (Ellison et al., (1982) EMBO J. 1403-407).

With respect to human antibody notecules reference is made to the LGG class in which an N-linked oilgosaccharide is attached to the amide side chain of Asn 297 of the β 4 bend of the inner face of the CH2 domain of the Fe region (Beale and Feinstein (1976), ORev, Biophys, 9-253-259; leftFrist et al. (1995) Immunol. Letts. 44:111-117). It is characteristic of the glycoprotein of the present invention that it contain or be modified to contain at least a CH2 domain. The CH2 domain is a CH2 domain of an immunoglobulin having a single N-linked oilgosaccharide of a human IgG CH2 domain. The CH2 domain is preferably the CHy2 domain of human IgG IgG.

The oligosaccharides of the present invention occur on the CH2 domain expressed as N-linked oligosaccharides. "N-linked glycorylation" refers to the attachment of the carbohydrate moiety via GleNAc to an asparagine residue in a pohypeptide chain. The N-linked carbohydrates all contain a common Man1-G(Man1-3)Manβ1-4GleNAcβ1-4GleNAcβ1-4GleNAcβ-R core structure. Therefore, in the core structure described, R represents an asparagine residue of the produced glycoprotein. The sequence of the protuced will contain an asparagine-X-streine, asparagine-X-treconine, and asparagine-X-cysteine, wherein X is any amino acid except proline. The skilled artisan will recognize that, for example, each of murine 1gG3, 1gG1, 1gG2B, 1gG2A and human 1gD, 1gG3, 1gG1, 1gG1, 1gG2 and 1gG4 CH2 domains have a single site for N-linked glycorylation at amino acid residue 297 (Kodat et al., Sequences of proteins of immunological interest Fifth Ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242L.

Of the N-linked carbohydrates the most important are the "complex" N-linked carbohydrates of the variety naturally occurring in immensoglobilin CHZ domains. According to the present invention such complex carbohydrates will be one of the "b-antennary" structures described herein. The core bi-antennary structure (GleNAc2Man3GleNAc) is typical of biantennary oligosaccharides and can be represented schematically as: GleNAc91-2Manos. Fuces.

> 6 6 Manβl-GlcNAcβl-4GlcNAc

GlcNAc61-2Manα∠

35

Since each binatennary structure may have a bisecting N-acetylglucoceamine, core fucose and either galactose or sialic acid outer saccharides, there are a total of 36 structurally unique oligosaccharides which may occupy the N-linked Am 297 site (Jefferis and Lund suora). It will also be reconsized that within a national record of the state of the state

CH2 domain, glycosylation at Asn 297 may be asymmetric owing to different ollossaccharide chains attached at either Asn 297 residue within the two chain Fe domain. For example, while the heavy chain synthesized within a single antibody-secreting cell may be homogeneous in its amino acid sequence, it is generally differentaly glycosylated resulting in a large number of structurally unique Ig glycoforms.

The major types of complex oligosaccharide structures found in the CH2 domain of the IgG are represented below.

5

According to the present invention GO refers to a biantennary structure wherein no terminal sialic acids (NeuAcs) or Gals are present, GI refers to a biantennary structure having one Gal and no NeuAcs and G2 refers to a biantennary structure with two terminal Gals and no NeuAcs. Accordingly, G-I refers to the core unit minus one GleNAc and G-2 refers to the core structure minus two GleNAcs.

The term "glycoform" as used within the context of the present invention is meant to denote a glycoprotein containing a particular carbohydrate structure or structures. Therefore, the G-2 glycoform of a CH2 domain refers to a CH2 domain having a G-2 glycan as defined herein.

5

The phrases "substantially homogeneous", "substantially uniform" and "substantial homogeneity" and
the like are used to indicate that the product is substantially devoid of by-products originating from undesired
glycoforms (e.g. G0 and G1). Expressed in terms of purity, substantial homogeneity means that the amount of
by-products does not exceed 10%, and preferably is below 5%, more preferably below 1%, most preferably
below 0.9%, wherein the percentages are by weight.

The phrases "substantially free of" and the like are used to indicate that the product is substantially devoid of by-products originating from undesired glycoforms (e.g. G0 and G1). Expressed in terms of purity, 15 substantially free means that the amount of by-products does not exceed 10%, and preferably is below 5%, more preferably below 1% most preferably below 0.5%, wherein the percentages are by weight.

The "CD20" antigen is expressed during early pre-B cell development and may regulate a step in cellular activation required for cell cycle initiation and differentiation. The CD20 antigen is expressed at high levels on neoplastic B cells however it is present on normal B cells as well. Anti-CD20 antibodies which recognize the CD20 surface antigen have been used clinically to lead to the targeting and destruction of neoplastic B cells (Maloney et al., (1994) Blood 84:2457-2466; Press et al., (1993) NEIM 329:12219-12223; Kaminski et al., (1993) NEIM 329; McLaughlin et al., (1996) Proc. Am. Soc. Clin. Oncol. 15:417). Chimeric and humanized anti-CD20 antibodies mediate complement dependent tysis of target B cells (Maloney et al. agupts). The monoclonal antibody CEB8 recognizes the human B cell restricted differentiation antigen Bp35 (Lin 25). Immunol. 139:3521; Maloney et al., (1994) Blood 84:2457). "C2B8" is defined as the anti-CD20 monoclonal antibody described in International Publication No. WO94/11026.

The terms antibody and immunoglobulins are used interchangeably and used to denote glycoproteins having the structural characteristics noted above for immunoglobulins.

The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies and unitodies and antibody compositions with polyepitopic specificity. The term "antibody" specifically covers monoclonal antibodies (nethodies (netho

(1992) Growth Factors, 7:53-64, and International Publication No. WO 96/30046; and anti-CD20, Maloney et al., (1994) Blood, 84:2457-2466, and Liu et al., (1987) J. Immunol., 130:3521-3526.

The term "preparation" as used herein is used to define a composition which has been identified and separated and/or recovered as component of its environment. Contaminant components of its environment are materials which would interfere with diagnostic or therapeutic uses for the glycoprotein such as unwanted or unintended glycoforms (G0 and G1), and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. The preparation of the invention is substantially free of these contaminants. In preferred embodiments, the glycoprotein preparation will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably silver stain.

The term "monoclonal antibody" (mAb) as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each mAb is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they can be synthesized by hybridoma culture, 20 uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., (1975) Nature, 256.489, or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 25 4.816.567 to Cability et al.).

The monoclonal antibodies herein include hybrid and recombinant antibodies produced by splicing a variable (including hypervariable) domain of an antibody with a constant domain (e.g. "humanized" antibodies), or a light chain with a heavy chain, or a chain from one species with a chain from another species, or fusions with heterologous proteins, regardless of species of origin or innumneglobulin class or subclass designation, (See, e.g., 30 U.S. Pat. No. 43,16,567 to Cabilly et al.; Mage and Lamoyi, in Monoclonal Antibody Production Techniques and Anpolications, pp. 79-97 (Marcel Dekker, Inc., New York, 1987).)

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies envived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they contain or are modified to contain at least one CH2 domain (Cabilly et al., supra; Morrison et al., (1984) Proc. Natl. Acad. Sci. U.S.A. 3.16542

-9-

"Humanized" forms of non-human (e.g., murine) antibodies are specific chimeric immunoglobulins. immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity, In some instances. Fy framework residues of the human immunoglobulin are replaced by corresponding nonhuman residues. Furthermore, humanized antibodies can comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further 10 refine and maximize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further 15 details see Jones et al., Nature 321:522 (1986); Reichmann et al., Nature 332:323 (1988); and Presta, Curr. Op. Struct. Biol. 2:593 (1992).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the "binding domain" of a heterologous protein (an "adhesin", e.g. a receptor, ligand or enzyme) with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of the 20 adhesin amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site (antigen combining site) of an antibody (i.e. is "heterologous") and an immunoglobulin constant domain sequence. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG1, IgG2, IgG2, or IgG4 subtypes, IgA, IgE, IgD or IgM. Immunoadhesins are described in, for example, U.S. Patent No. 5,116,964.

As used herein the phrase "multispecific immunoadhesin" designates immunoadhesins (as hereinabove defined) having at least two binding specificities (i.e. combining two or more adhesin binding domains), Multispecific immunoadhesins can be assembled as heterodimers, heterotrimers or heterotetramers, essentially as disclosed in WO 89/02922 (published 6 April 1989), in EP 314,317 (published 3 May 1989), and in U.S. Patent No. 5.116.964 issued 2 May 1992. Preferred multispecific immunoadhesins are bispecific. Examples 30 of bispecific immunoadhesins include CD4-1gG/TNFreceptor-1gG and CD4-1gG/L-selectin-1gG. The last mentioned molecule combines the lymph node binding function of the lymphocyte homing receptor (LHR, Lselectin), and the HIV binding function of CD4, and finds potential application in the prevention or treatment of HIV infection, related conditions, or as a diagnostic.

25

An "antibody-immunoadhesin chimera (Ab/la chimera)" comprises a molecule which combines at least 35 one binding domain of an antibody (as herein defined) with at least one immunoadhesin (as defined in this application). Exemplary Ah/Ia chimeras are the bispecific CD4-IgG chimeras described by Berg et al., supra and Chamow et al., supra, Immunoadhesons include CD4 (Capon et al., (1989) Nature 337:525-531; Traunecker et al., (1989) Nature 339:68-70; and Byrn et al., (1990) Nature 344:667-670); L-selectin or homing receptor (Watson et al., (1990) J. Cell. Biol. 110:2221-2229; and Watson et al., (1991) Nature 349:164-167); CD44

(Aurifo et al., (1990) Cell (i:1303-1313; CD28 and B7 (Linsley et al., (1991) J. Exp. Med. 173:721-730);
CTLA-4 (Lisley et al., J. Exp. Med. 174:561-569); CD22 (Stamenkovic et al., Cell 66:1133-1144); TNF receptor
(Ashkenazi et al., (1991) Proc. Natl. Acad. Sci. USA 83:10353-10339; Lesslawer et al., (1991) Exr. J. limmunol.
27:2883-2886; and Peppel et al., (1991) J. Exp. Med. 174:1483-1489); NP receptors (Bennett et al., (1991) J.
5 Biol. Chem. 266:23060-23067; interferon y receptor (Kurschner et al., (1992) J. Biol. Chem. 267:9354-9360;
4-1BB (Chaluppy et al., (1992) PNAS USA 89:10360-10364) and IgE receptor a (Ridgway and Gorman, (1991) J. Cell. Biol. 115. Abstract No. 1448).

Examples of homomultimeric immunoadhesins which have been described for therapeutic use include the CD4-IgG immunoadhesin for blocking the binding of HIV to cell-surface CD4. Data obtained from Phase I clinical trials in which CD4-IgG was administered to pregnant women just before delivery suggests that this immunoadhesin may be useful in the prevention of maternal-fetal transfer of HIV. Ashkenazi (1991) et al., intern. Rev. Immunol. 10:219-227. An immunoadhesin which binds numor necrosis factor (TNF) has also been developed. TNF is a proinflammatory cytokine which has been shown to be a major mediator of septic shock. Based on a mouse model of septic shock, a TNF receptor immunoadhesin has shown promise as a candidate for 15 clinical use in treating septic shock (Ashkenazi, A. et al. (1991) PNAS USA 82: (0535-10539)

If the two arms of the immunoadhesin structure have different specificities, the immunoadhesin is called a "bispecific immunoadhesin" by analogy to bispecific antibodies. Dietsch et al., (1993) J. Immunol. Methods 162:123 describe such a bispecific immunoadhesin combining the extracellular domains of the adhesion molecules, E-selectin and P-selectin, each of which selectins is expressed in a different cell type in nature.

20 Binding studies indicated that the bispecific immunoglobulin fusion protein so formed had an enhanced ability to bind to a myeloid cell line compared to the monospecific immunoadhesins from which it was derived.

The invention also permins to immunoconjugates comprising the antibody described herein conjugated to a cytotoxic agent such as a chemotherspecial cagent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

In another embodiment, the antibody may be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a radionuclide).

25

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in 30 need of treatment include those already with the disorder as well as those prone to have the disorder or those in which the disorder is to be prevented.

The terms "treating," "treatment," and "therapy" refer to curative therapy, prophylactic therapy, and preventative therapy.

The term "mammal" refers to any animal classified as a mammal, including humans, cows, horses, dogs

35 and cats. In a preferred embodiment of the invention, the mammal is a human.

As used herein, protein, peptide and polypeptide are used interchangeably to denote an amino acid polymer or a set of two or more interacting or bound amino acid polymers.

The term "disease state" refers to a physiological state of a cell or of a whole mammal in which an interruption, cessation, or disorder of cellular or body functions systems, or organs has occurred.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gestric cancer, pancreatic cancer, gital cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepsatoma, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepsatic carcinoma and various twes of head and neck cancer.

The term "inflammatory disorder" refers to a fundamental pathologic process consisting of a dynamic

complex of cytologic and histologic reactions that occur in the affected blood vessels and adjacent tissues in
response to an injury or abnormal stimulation caused by a physical, chemical, or biologic agent, including: 1)
the local reactions and resulting morphologic changes, 2) the destruction or removal of the injurious material,
3) the responses that lead to repair and healing. Inflammatory disorders treatable by the invention are those
wherein the inflammation is associated with cytokine-induced disorders, such as those associated with interleukin
and leukemia inhibitory factor cytokines. Such disorders include abnormalities in thrombopoiesis, macrophage
growth and differentiation, proliferation of hematopoietic progenitors, and the like.

The term "neurological disorder" refers to or describes the physiological condition in mammals that is typically characterized by nerve cell growth, differentiation, or cell signaling. Examples of neurological disorders include, but are not limited to, neurofixonasosis and peripheral neuropathy.

The term "cardiac disorder" refers to or describes the physiological condition in mammals that is typically characterized by cardiac cell growth and differentiation. An example of a cardiac disorder includes, but is not limited to, cardiac hypertrophy and heart failure, including congestive heart failure, myocardial infaction, and tachyrhythmia. "Heart failure" refers to an abnormality of cardiac function where the heart does not pump blood at the rate needed for the requirements of metabolizine tissues.

25 Modes for Carrying out the Invention

20

The compositions and preparations of the present invention are preferably obtained by in vitro modification of recombinantly produced glycoproteins. The skilled artists will recognize that both the structure of the attached oligosaccharide and the efficiency of glycosylation of a glycoprotein produced in recombinant cell culture will vary depending upon the method of glycoprotein production employed. Oligosaccharide 30 structures attached at particular glycosylation sites will generally vary even for monoclonal antibodies. Therefore, it is typical to find multiple glycoforms within a given production or batch for monoclonal as well as polyclonal antibodies.

According to the invention, a compositions is prepared comprising a glycoprotein having an immunoglobulin CH2 domain wherein the CH2 domain has at least one N-linked oligoaccharide wherein substantially all of the oligoaccharide of the CH2 domain is a G-2 oligoaccharide as defined herein. The invention further provides for the preparation of a compositions comprising a glycoprotein having at least one immunoglobulin CH2 domain wherein the N-linked oligoaccharides of the CH2 domain are substantially of the C2 and G-2 variety. The composition is substantially free of glycoproteins comprising an immunoglobulin CH2 domain wherein the N-linked oligoaccharide is a G1, G0 or G-1 oligoaccharide the N-linked oligoaccharide is a G1, G0 or G-1 oligoaccharide.

The present invention provides that a substantially homogenous glycoform can be obtained and that, according to certain embodiments, the glycoform exhibits a favorable bioactivity compared with the heterogenous glycoform. According to the present invention a substantially homogenous glycoform of a glycoprotein comprising a CH2 domain, such as an antibody, is obtained. Compositions comprising the glycoprotein glycoform are prepared which are substantially free of undesired glycoforms. Therefore, according to one aspect of the present invention, a composition comprising a glycoprotein having a CH2 domain such as, for example, an IgG1 type antibody containing a single site for N-linked glycosylation in each CH2 domain and having a particular N-linked oligosaccharide is prepared. In one embodiment the antibody glycoform is a G2 glycoform. In a further embodiment, the antibody is a G-2 glycoform. A further aspect of the present invention provides for a composition as described, being substantially free of G1, G0 and G-1 antibody glycoforms. This composition combines the G2 and G-2 antibody evelocforms of the present invention.

The glycoproteins, for example antibodies of the present invention can be produced by well known techniques including but not limited to gene expression systems to allow the production of intact glycoproteins comprising a CH2 domain in any of a variety of host systems. Both prokaryotic and eukaryotic expression systems, for example can be used in the production of the glycoproteins of the present invention however, eukaryotic expression systems are preferred since antibodies produced in prokaryotic cell systems lack carbohydrate.

Isolating Antibodies

Techniques for isolating antibodies and preparing immunoathesins follow. However, it will be appreciated that the glycoprotein can be isolated using techniques which are known in the art.

(i) Antibody preparation

Several techniques for the production of antibodies have been described which include the traditional hybridoma method for making monoclonal antibodies, recombinant techniques for making antibodies (including chimeric antibodies, e.g. humanized antibodies), antibody production in transgenic animals and the recently described phage display technology for preparing "fully human" antibodies. These techniques shall be described briefly below.

Polyclonal antibodies to the antigen of interest generally can be raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may be useful to conjugate the antigen (or a fragment containing the target amino acid sequence) to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivativing agent, for example maleimidobeazoy laulfouscoinimide ester (conjugation through cysteine residues), N-hydroxysuccinlanide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl₂, or R¹N²C-NR, where R and R¹ are different alkyl groups. Animals are immunized against the immunogenic conjugates or derivatives by combining 1 mg of 1 mg of conjugate (for rabbits or mice, respectively) with 3 volumes of Freud's complete adjuvant and injecting the solution intradernally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freud's complete adjuvant by subcutaneous injection at multiple sites. 7 to 14 days later the animals are bled and the scrum is assayed for araibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-

linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies using the hybridoma method first described by Kohler & Milstein, (1975) Nature 256:495 or may be made by 5 recombinant DNA methods (Cabilly et al., U.S. Patent No. 4,816,567). In the hybridoma method, a mouse or other appropriate host animal, such as hamster, is immunized as hereinabove described to elicit lymphocytes that produce, or are capable of producing, antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: 10 Principles and Practice, pp.59-103 [Academic Press, 1986]). The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the 15 growth of HGPRT-deficient cells. Preferred mycloma cells are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego. California USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA. 20 Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, (1984) J. Immunol., 133:3001; and Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63, Marcel Dekker, Inc., New York, 1987). See, also, Boerner et al., (1991) J. Immunol., 147(1):86-95 and WO 91/17769, published Nov 28, 1991, for techniques for the production of human monoclonal antibodies. Culture medium in which hybridoma eells are growing is assayed for production of monoclonal antibodies directed against the antigen of interest. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson & Pollard, (1980) Anal. Biochem. 107:220. After hybridoma cells are identified that produce 30 antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods. Goding, Monoclonal Antibodies: Principles and Practice, pp.59-104 (Academic Press, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium or RPM1-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal. The monoclonal antibodies secreted by the subclones are suitably separated from the 35 culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

Alternatively, it is now possible to produce transgenic animals (e.g. mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin

production. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region (I_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodics upon antigen challenge. See, e.g., Jakobovits et al. (1993) Proc.

Natl. Acad. Sci. USA 90:2551-255 and Jakobovits et al., (1993) Nature 36:2:255-258.

In a further embodiment, antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., (1990) Nature, 348:552-554 (1990), using the antigen of interest to select for a suitable antibody or antibody fragment Clackson et al., (1991) Nature, 352:624-628 (1991) and Marks et al., (1991) J. Mol. Biol., 22:581-597 describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Mark et al., (1992) Bio/Technol. 10:779-783), as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al., (1993) Nuc. Acids Res., 21:2265-2266). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of "monoclonal" antibodies (especially human antibodies) which are encompassed by the present invention.

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These nonhuman amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers 20 (Jones et al., (1986) Nature 321:522-525; Riechmann et al., (1988) Nature 332:323-327; Verhoeven et al., (1986) Science 239:1534-1536), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (Cabilly, supra), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR 25 residues, and possibly some FR residues, are substituted by residues from analogous sites in rodent antibodies. It is important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are 30 familiar to those skilled in the art. Computer programs are available which illustrate and display probable threedimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. For further details see WO 92/22653, published Dec 23, 1992,

Immunoglobulins (gg) and certain variants thereof are known and many have been prepared in recombinant cell culture. For the antibodies described above, the use of human IgG₂ immunoglobulin sequences is preferred since this structure contains the CFE domain of the present invention. For example, see U.S. Patent

No. 4,745,055; EP 256,654; Faulkner et al., (1982) Nature 298:286; EP 120,694; EP 125,023; Morrison, J. Immun. 123:793 (1979); Köhler et al., (1980) Proc. Natl. Acad. Sci. USA 77:2197; Raso et al., (1981) Cancer Res. 41:2073; Morrison et al., (1984) Ann. Rev. Immunol. 2:239; Morrison, (1985) Science 229:1202; Morrison et al., (1984) Proc. Natl. Acad. Sci. USA 81:6851; EP 255,694; EP 266,663; and WO 88/03559.

Preferred antibodies within the scope of the present invention include anti-IL-8 (St John et al., (1993). Chest, 103:932 and International Publication No. WO 95/23865); anti-CD11a (Filcher et al., Blood, 77:249-256. Steppe et al., (1991), Transplant Inti. 4:3-7, and Hourmant et al., (1994), Transplantation 58:377-380); anti-IgE (Presta et al., (1993), J. Immunol. 151:2623-2632, and International Publication No. WO 95/19181); anti-HER2 (Carter et al., (1992), Proc. Natl. Acad. Sci. USA, 89:4285-4289, and International Publication No. WO 10 92/20798); anti-VEGF (Jin Kim et al., (1992) Growth Factors, 7:53-64, and International Publication No. WO 96/30046); and anti-CD20 (Maloney et al., (1994) Blood, 84:2457-2466, Liu et al., (1987) J. Immunol. 130:3521-3526).

(ii) Immunoadhesin preparation

30

Chimeras constructed from an adhesin binding domain sequence linked to an appropriate 15 immunoglobulin constant domain sequence (immunoadhesins) are known in the art. Immunoadhesins reported in the literature include fusions of CD4 (Capon et al., (1989) Nature 337:525-531; Traunecker et al., (1989) Nature 339:68-70; Zettmeissl et al., (1990) DNA Cell Biol. USA 9:347-353; and Byrn et al., (1990) Nature 344:667-670); L-selectin (homing receptor) (Watson et al., (1990) J. Cell. Biol. 110:2221-2229; and Watson et al., (1991) Nature 349:164-167); CD44 (Aruffo et al., (1990) Cell 61:1303-1313); CD28 and B7 (Linsley et al., 20 (1991) J. Exp. Med. 173:721-730); CTLA-4 (Lisley et al., (1991) J. Exp. Med. 174:561-569); CD22 (Stamenkovic et al., (1991) Cell 66:1133-1144); TNF receptor (Ashkenazi et al., (1991) Proc. Natl. Acad. Sci. USA 88:10535-10539; Lessiauer et al., (1991) Eur. J. Immunol. 27:2883-2886; and Peppel et al., (1991) J. Exp. Med. 174:1483-1489); and IgE receptor α (Ridgway and Gorman, (1991) J. Cell, Biol. 115: Abstract No. 1448).

Typically, in such fusions the encoded chimeric polypeptide will retain at least functionally active hinge. 25 CH2 and CH3 domains of the constant region of an immunoglobulin heavy chain. Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the CH1 of the heavy chain or the corresponding region of the light chain. The precise site at which the fusion is made is not critical; particular sites are well known and may be selected in order to optimize the biological activity, secretion, or binding characteristics of the la.

In a preferred embodiment, the adhesin sequence is fused to the N-terminus of the Fc domain of immunoglobulin G1 (IgG1). It is possible to fuse the entire heavy chain constant region to the adhesin sequence. However, more preferably, a sequence beginning in the hinge region just upstream of the papain cleavage site which defines IgG Fc chemically (i.e. residue 216, taking the first residue of heavy chain constant region to be 114), or analogous sites of other immunoglobulins is used in the fusion. In a particularly preferred embodiment. 35 the adhesin amino acid sequence is fused to (a) the hinge region and CH2 and CH3 or (b) the CH1, hinge, CH2 and CH3 domains, of an IgG, heavy chain. The precise site at which the fusion is made is not critical, and the optimal site can be determined by routine experimentation.

For bispecific immunoadhesins, the immunoadhesins are assembled as multimers, and particularly as heterodimers or heterotetramers. Generally, these assembled immunoglobulins will have known unit structures.

A basic four chain structural unit is the form in which IgG, IgD, and IgE exist. A four chain unit is repeated in the higher molecular weight immunoglobulins; IgM generally exists as a pentamer of four basic units held together by disulfide bonds. IgA globulin, and occasionally IgG globulin, may also exist in multimeric form in serum. In the case of multimer, each of the four units may be the same or different.

5 Various exemplary assembled immunoadhesins within the scope herein are schematically diagramed below:

(a)
$$AC_{H^{-}}[AC_{H^{+}}AC_{L^{-}}AC_{H^{+}}AC_{L^{-}}V_{H^{-}}C_{H^{+}}$$
 or $V_{L^{-}}C_{L^{-}}AC_{H^{+}}]$;
(b) $AC_{L^{-}}AC_{H^{-}}[AC_{L^{-}}AC_{H^{-}}AC_{L^{-}}V_{H^{-}}C_{H^{-}}V_{L^{-}}C_{L^{-}}AC_{H^{-}}$ or $V_{L^{-}}C_{L^{-}}AC_{H^{-}}$;
(c) $AC_{L^{-}}V_{H^{-}}C_{H^{-}}[AC_{H^{-}}$ or $AC_{L^{-}}V_{H^{-}}C_{H^{-}}$ or $V_{L^{-}}C_{L^{-}}AC_{H^{-}}]$;

(d) $V_L C_L \text{-}AC_H \text{-}[AC_L \text{-}V_H C_H, \text{ or } V_L C_L \text{-}AC_H];$ and

(e) $[A-Y]_n - [V_L C_L - V_H C_H]_2$,

10

15

wherein each A represents identical or different adhesin amino acid sequences;

 ${\sf V}_{\sf L}$ is an immunoglobulin light chain variable domain;

V_H is an immunoglobulin heavy chain variable domain;

 C_L is an immunoglobulin light chain constant domain; C_H is an immunoglobulin heavy chain constant domain;

n is an integer greater than 1:

Y designates the residue of a covalent cross-linking agent.

In the interests of brevity, the foregoing structures only show key features; they do not indicate joining

(1) or other domains of the immunoglobulins, nor are distulfide bonds shown. However, where such domains are
required for binding activity, they shall be constructed to be present in the ordinary locations which they occupy
in the immunoglobulin molecules.

Alternatively, the adhesin sequences can be inserted between immunoglobulin heavy chain and light chain sequences, such that an immunoglobulin comprising a chimeric heavy chain is obtained. In this cmbodiment, the adhesin sequences are fused to the 3' end of an immunoglobulin heavy chain in each arm of an immunoglobulin, either between the hinge and the CH2 domain, or between the CH2 and CH3 domains, Similar constructs have been reported by Hoogenboom, et al., (1991) Mol. immunol. 28:1027-1037).

Although the presence of an immunoglobulin light chain is not required in the immunosdhesins of the present invention, an immunoglobulin light chain might be present either covalently associated to an adhesinimmunoglobulin heavy chain fusion polypeptide, or directly fused to the adhesin. In the former case, DNA encoding an immunoglobulin light chain is typically coexpressed with the DNA encoding the adhesinimmunoglobulin heavy chain fusion protein. Upon secretion, the hybrid heavy chain and the light chain will be
covalently associated to provide an immunoglobulin-like structure comprising two disulfide-linked
immunoglobulin heavy chain-light chain pairs. Methods suitable for the preparation of such structures are, for
example, disclosed in U.S. Patent No. 4,816,567, issued 28 March 1989.

Immunoadheains are most conveniently constructed by fusing the cDNA sequence encoding the adhesin portion in-frame to an Ig cDNA sequence. However, fusion to genomic Ig fragments can also be used (see, e.g., Aruffo et al., (1990) Cell 61:1303-1313; and Stumenkovic et al., (1991) Cell 66:1133-1144). The latter type of fusion requires the presence of Ig regulatory sequences for expression. cDNAs encoding IgG heavy-chain

constant regions can be isolated based on published sequences from cDNA libraries derived from spleen or peripheral blood lymphocytes, by hybridization or by polymerase chain reaction (PCR) techniques. The cDNAs encoding the "adhesin" and the Ig parts of the immunoadhesin are inserted in tandem into a plasmid vector that directs efficient expression in the chosen host cells.

In a preferred embodiment, the immunoglobulin sequences used in the construction of the glycoproteins such as the antibodies and immunoadhesins of the present invention are from an IgG immunoglobulin heavy chain CH2 constant domain. For example, the use of human IgG1 immunoglobulin sequences is preferred because this structure contains the preferred CH2 domain of the present invention. A major advantage of using IgG, is that IgG1 can be purified efficiently on immobilized protein A. In contrast, purification of IgG3 requires 10 protein G, a significantly less versatile medium. However, other structural and functional properties of immunoglobulins should be considered when choosing the lg CH2 domain for a particular glycoprotein. For example, the IgG3 hinge is longer and more flexible, so it can accommodate larger "adhesin" domains that may not fold or function properly when fused to IgG1. Another consideration may be valency; IgG immunoadhesins are bivalent homodimers, whereas Ig subtypes like IgA and IgM may give rise to dimeric or pentameric 15 structures, respectively, of the basic Ig homodimer unit. For antibodies and immunoadhesins designed for in vivo application, the pharmacokinetic properties and the effector functions specified by the Fc region are important as well. Although IgG1, IgG2 and IgG4 all have in vivo half-lives of 21 days, their relative potencies at activating the complement system are different. IgG4 does not activate complement, and IgG2 is significantly weaker at complement activation than IgG1. Moreover, unlike IgG1, IgG2 does not bind to Fc receptors on mononuclear cells or neutrophils. this may be due to the differences in CH2 domains utilized in these isotypes. While IgG2 is optimal for complement activation, its in vivo half-life is approximately one third of the other IgG isotypes. Another important consideration for immunoadhesins designed to be used as human therapeutics is the number of allotypic variants of the particular isotype. In general, IgG isotypes with fewer serologicallydefined allotypes are preferred. For example, IgG 1 has only four serologically-defined allotypic sites, two of 25 which (G1 m and 2) are located in the Fc region; and one of these sites, G1 m I, is non-immunogenic. In contrast, there are 12 serologically-defined allotypes in IgG3, all of which are in the Fc region; only three of these sites (G3m5, II and 2I) have one allotype which is nonimmunogenic. Thus, the potential immunogenicity of a v3 immunoadhesin is greater than that of a \(1 \) immunoadhesin. Preferred among the immunoadhesins are those comprising at least the IgGI CH2 domain as described herein above.

Preparing the Glycoprotein

5

30

DNA encoding the glycoproteins of the invention is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of the glycoprotein, for example monoclonal antibodies, in the recombinant host cells.

Various techniques for making and isolating antibody and immunoadhesins and the like directly from recombinant cell culture have also been described. In particular, the cells which express the desired glycoprotein

should express or be manipulated to express the particular enzymes such that under the appropriate conditions, the appropriate post-translational modification occurs in vivo. The enzymes include those enzymes necessary for the addition and completion of N- and O- linked carbohydrates such as those described in Hubbard and Ivan supra for N-linked oligosaccharides. The enzymes optionally include oligosaccharyltransferase, alphaglucosidase 1, alpha-glucosidase 11, ER alpha(1,2)mannosidase, Golgi alpha-mannosidase 1, Nacetylyglucosaminyltransferase I, Golgi alpha-mannosidase II, N-acetylyglucosaminyltransferase II, alpha(1,6)fucosyltransferase, and β(1,4)galactosyltransferase.

Typically, the cells are capable of expressing and secreting large quantities of a particular glycoprotein of interest into the culture medium. Examples of suitable mammalian host cells within the context of the present 10 invention may include Chinese hamster ovary cells/-DHFR (CHO, Urlanb and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 [1980]); dp12.CHO cells (EP 307,247 published 15 March 1989); monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36:59 [1977]); baby hamster kidney cells (BHK. ATCC CCL 10); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 [1980]); monkey kidney cells 15 (CVI ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annais N.Y. Acad. Sci., 383:44-68 [1982]); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).

Preferred host cells include Chinese hamster ovary cells/-DHFR (CHO, Urlanb and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 [1980]); dp12.CHO cells (EP 307,247 published 15 March 1989).

20

30

For the culture of the mammalian cells expressing the desired protein and capable of adding the desired carbohydrates at specific positions, numerous culture conditions can be used paying particular attention to the host cell being cultured. Suitable culture conditions for mammalian cells are well known in the art (J. Immunol. 25 Methods (1983)56:221-234) or can be easily determined by the skilled artisan (see, for example, Animal Cell Culture: A Practical Approach 2nd Ed., Rickwood, D. and Hames, B.D., eds. Oxford University Press, New York (1992)), and vary according to the particular host cell selected.

The glycoprotein of interest preferably is recovered from the culture medium as a secreted polypeptide, although it also may be recovered from host cell lysates.

As a first step, the culture medium or lysate is centrifuged to remove particulate cell debris. The polypertide thereafter is purified from contaminant soluble proteins and polypertides, with the following procedures being exemplary of suitable purification procedures: by fractionation on immunoaffinity or ionexchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for 35 example, Sephadex G-75; and protein A Sepharose columns to remove contaminants such as IgG. A protease inhibitor such as phenyl methyl sulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification. One skilled in the art will appreciate that purification methods suitable for the polypeptide of interest may require modification to account for changes in the character of the polypeptide upon expression in recombinant cell culture.

Especially preferred within the context of the present invention are purification techniques and processes which select for the carbohydrates of the invention.

Preparation of G2 Glycoforms

The attachment of a galactose residue to an existing glycan involves the transfer of a galactose moiety from an activated galactose containing compound to the glycasyl moiety of the CH2 domain. The transfer of galactose is catalyzed by a galactosyltransferase enzyme.

While the skilled artisan will recognize that any of several art standard procedures can be employed for the addition of a sugar to a preexisting oligosaccharide chain, the invention preferably utilizes those procedures that result in complete galactosylation of the sample as described herein. By complete galactosylation of the sample is meant that each antennary structure of the native biantennary oligosaccharide terminates in a galactose residue. More particularly the reaction is complete if substantially all N-linked oligosaccharides are of the G2 variety.

According to the present invention a method for producing the compositions of the invention comprising the steps of reacting in an aqueous buffered solution at a temperature of about 25-40 C;

15 a) a metal salt at a concentration of about 5 mM to about 25 mM;

b) an activated galactose at a concentration of about 5 mM to about 50 mM;

e) a galactosyltransferase at a concentration of about 1 mUnit/ml to about 100 mUnit/ml; and
 d) a substrate glycoprotein; and

recovering the glycoprotein.

20

As used herein the term galactose (gal) and galactose residue and the like refer to D and L (+/-) galactose. Preferably the gal is D-(+)-galactose which has been reported as a naturally occurring gal in various animal species.

The activated galactose containing compound is generally a uridine diphosphate (UDP)-galactose.

Uridine diphosphate-galactose and other donor sugars, which are capable of transferring galactose to N-linked
olicosoccharides.

Metal salts include for example, MnCl2, BaCl2, CaCl2, and others.

The galactosyl transferase used in accordance with the present invention is preferably a β1-4 transferase and catalyzes the transfer of a galactose moiety from the activated substrate to the glycosyl compound. The galactosyltransferase enzymes are substrate specific and are named according to their substrate specificity. The 30 galactosyltransferase designated beta 1-4 refers to a galactosyl transferase that catalyzes the transfer of galactose to the hydroxyl group of a glycosyl acceptor compound. Exemplary galactosyltransferases useful within the context of the present invention are from human, bovine, mouse, hamster, or, monkey origin.

Galactosyltransferases are commercially available (Sigma Chemical Co., St. Louis, Mo.; Bochringer Mannheim, Indianapolis, Ind. and Genzyme, Cambridge MA). Alternatively galactosyl transferases are isolated and purifiled from animal tissue such as bovine (Boeggeman et al., (1993) Prot. Eng. 6(7):779-785;human Schweinteck (1994) Gene 145(2):299-303; Kleene et al., (1994) Biochem. Biophys. Res. Commun. 201(1):160-167; Chatterjee et al., (1995) Int. J. Blochem Cell. Biol. 27(3):329-336; Herrmann et al., (1995) Protein. Expr. Purif. 6(1):72-78).

The concentration and amount of the various reactants described above depend upon a number of factors including reaction conditions such as temperature and pH and the amount of glycoprotein to be galactosylated. While the present method is thought to be generally applicable to all glycoproteins preferred glycoproteins for use in the present method are glycoproteins comprising at least the CH2 domain of immunoclobulins as described above.

The galactosyltransferase is used in a catalytic amount. By catalytic amount is meant an amount of galactosyltransferase at least sufficient to catalyze in a non-rate-limiting manner the conversion of the enzyme's substrate to product. The entalytic amount of a particular enzyme varies according to the amount of a particular enzyme substrate as well as reaction conditions such as temperature, time and pH value. Enzyme amounts are 10 generally expressed in activity units. One unit catalyzes the formation of 1 µmol of product at a given temperature (typically 37° C) and pH value (typically 7.5) per minute. Thus 10 units of an enzyme is the catalytic amount of that enzyme such that 10 µmol of substrate are converted to 10 µmols of product in one minute at a temperature of 37° C and a HJ of 6.5 to 7.5.

The reaction comprises mixing at least the above ingredients in a suitable aqueous environment to form

a reaction mixture and maintaining the reaction mixture under the conditions of temperature, pH, osmolality, ionic composition and ambient temperature for a secried of time sufficient to complete the reaction.

The selection of particular conditions depends primarily upon the amount of glycoprotein present. The temperature can range from about 20 C to about 40 C. The Felf value can range from about 6.0 to about 10.0 preferably the ept value is from about 6.5 to about 40 C. The Fl value can range from about 6.0 to about 11.0 preferably the pH value is from about 6.5 to about 20 8.5 and more preferably about 7.5. The pH is maintained by the addition of a suitable buffer to the reaction. The buffer is devoid of phosphate, EDTA, EGTA and other chelators that bind Mg++ or Mn++. The selection of buffer is based upon the ability of the buffer to maintain the pH at about the desired pH level. Where the pH value is 7.5 the preferred buffers are sodium cacodylate and MISS.

In an exemplary method, the glycoprotein samples (e.g. C2BS, anti-HER2, anti-VEGF, anti-IgE and
25 TNFR-IgG) at 10 mg in 0.5 ml, are buffer exchanged into 50 ml/s sodium caccodylate buffer, pH 7.1 (final vol.
1.0 ml). 50 µl each of 100 ml/UDP-Gal and 100 ml/M MnCl₂ are added to the glycoprotein solution. The 61,4galactosyltransferase (B1,4GT; lyophilizzed prowder) is reconstituted in 50 ml/s sodium caccodylate buffer, pH 7.1,
at a concentration of 1 ml/ml. 50 µl of this solution is added to the reaction mixture and incubated at 37 of C for
48 hr. The reaction is stopped by cooling the reaction vial on ice (4 of C) for 10 min and the galactosylated
30 antibody is purified on a rottein A column.

Preparation of G-2 Glycoforms

The removal of a galactose and an N-acetylglucosamine residue from an existing glycan can be accomplished by methods known to those skilled in the art and involves the use of appropriate enzymes for the removal of the particular residue. Removal of galactose residues is accomplished using galactosidases that recognize the terminal galactose as substrate. Appropriate galactosidases are known to those skilled in the art and include 6-D-galactosidases from Diplococcus pneumonice, jack bean, bovine testis, an chicken liver.

Likewise, removal of terminal N-acetylglucosamine structures can be accomplished using appropriate N-acetylglucosaminidases available to the skilled artisan. Appropriate enzymes for the removal of N-

acetylglucasamine terminal residues include N-acetyl β -D-glucosamindases from Diplococcus pneumoniae, jack bean, and bovine testis and chicken liver.

While the skilled artisan will recognize that any of several art standard procedures can be employed for the removal of a sugar from a preexisting oligosaccharide chain, the invention preferably utilizes a procedures that results in complete degalactosylation of the sample as well as complete removal of N-acetylglucosamine. By complete degalactosylation of the sample is meant that each antennary structure of the native biantennary oligosaccharide terminates in an N-acetylglucosamine residue following the removal procedure. More particularly the reaction is complete if substantially all N-linked oligosaccharides are of the G0 variety following treatment. Likewise, by complete removal of N-acetylglucoseamine is meant that each antennary structure of the native biantennery oligosaccharide terminates with a mannose residue following the removal procedure. More particularly the reaction is complete if substantially all N-linked oligosaccharides are of the G-2 variety following treatment.

An exemplary procedure employs two appropriate enzymes in a single step procedure. For example, a glycoprotein comprising a CHZ domain such as an antibody (S-10 mg) is buffer-exchanged into 100 mM is citrate-phosphate buffer, pH 5.0, using NAP-5 columns (Pharmacia). β-Galactosidase (40 mU/mg protein, Diplococcus pneumoniae, Boehringer Mannheim) and N-acetyl-β-D-glucosaminidase (40 mU/mg protein, Diplococcus pneumoniae Boehringer Mannheim or jack beain enzyme from Sigma) are added to 5-10 mg ailquots of protein and incubated at 37°C for 12-24 hrs. The IgG samples are purified on a Protein A column. The purified protein is subjected to electrospresy ionization mass spectrometry, capillary electrophoresis for carbohydrate analysis to confirm complete removal of the galactose and N-acetylglucosamine residues.

Analysis of the Glycoprotein

The complex carbohydrate portion of the glycoprotein produced by the processes of the present invention may be readily analyzed to determine that the reaction described above is complete. The oligosaccharide are analyzed by conventional techniques of carbohydrate analysis such as those described in the accompanying Figures and Examples. Thus, for example, techniques such as lectin blotting, well-known in the art, reveal proportions of terminal mannose or other sugars such as galactose.

The carbohydrate structures of the present invention occur on the protein expressed as G2 or G-2 Nlinked oligosaccharides. Several methods are known in the art for glycooplation analysis and are useful in the
context of the present invention. Such methods provide information regarding the identity and the composition
of the oligosaccharide attached to the peptide. Methods for carbohydrate analysis useful in the present invention
include but are not limited to lectin chromatography; HPAEC-PAD, which uses high pH anion exchange
chromatography to separate oligosaccharides based on charge; NMR; Mass spectrometry; HPLC; GPC;
monosaccharide compositional analysis; sequential enzymatic digestion.

Additionally, methods for releasing oligosaccharides are known. These methods include 1 jenzymatic, which is commonly performed using peptide-N-ejlycosidase F/endo-fj-galactosidase; 2) elimination using harsh alkaline environment to release mainly 0-linked structures; and 3) ehemical methods using anhydrous hydrazine to release both N-and O-linked oligosaccharides

Analysis can be performed using the following steps:

 Dialysis of the sample against deionized water, to remove all buffer salts, followed by lyophilization.

- Release of intact oligosaccharide chains with anhydrous hydrazine.
- Treatment of the intact oligosaccharide chains with anhydrous methanolic HCl to liberate individual monosaccharides as O-methyl derivative.
 - N-acetylation of any primary amino groups.

20

- 5. Derivatization to give per-O-trimethylsilyl methyl glycosides.
- Separation of these derivative, by capillary GLC (gas -liquid chromatography) on a CP-SIL8 column.
- 7. Identification of individual glycoside derivatives by retention time from the GLC and mass spectroscopy, compared to known standards.
 - 8. Quantitation of individual derivatives by FID with an internal standard (13-O-methyl-D-glucose).

Neutral and amino-sugars can be determined by high performance anion-exchange chromatography
15 combined with pulsed amperometric detection (HPAE-PAD Carbohydrate System, Dionex Corp.). For instance,
sugars can be released by hydrolysis in 20% (w/v) trifluoroacetic acid at 100 C for 6 h. Hydrolysates are then
dried by lyophilization or with a Speed-Vac (Savant Instruments). Residues are then dissolved in 11% sodium
acetate trihydrate solution and analyzed on a HPLC-AS6 column as described by Anumula et al. (Anal. Biochem.
193:269-280 (1991).

Sialic acid can be determined separately by the direct colorimetric method of Yao et al. (Anal Biochem. 179:332-335 (1989)) in triplicate samples. In a preferred embodiment the thiobarbaturic acid (TBA) of Warren, L. J. Biol Chem 238:(3) (1959) is used.

Alternatively, immunoblot carbohydrate analysis may be performed. According to this procedure protein-bound carbohydrates are detected using a commercial glycan detection system (Boehringer) which is 25 based on the oxidative immunoblot procedure described by Haselbeck and Hosel [Haselbeck et al. Cllycoconjugate 1, 7:63 (1990)]. The staining protocol recommended by the manufacturer is followed except that the protein is transferred to a polyvinylidene difluoride membrane instead of nitrocellulose membrane and the blocking buffers contained 5% bovine serum almon in 10 mM tris buffer, pH 7.4 with 0.9% sodium chloride. Detection is made with anti-digoxigenin antibodies linked with an alkaline phosphate conjugate 30 (Boehringer), 1:1000 dilution in tris buffered saline using the phosphates substrates, 4-nitroblue tetrazolium chloride, 0.03% (w/w) and 5-bromo-4 chloro-3-indoyl-phosphate 0.03% (w/w) in 100 mM tris buffer, pH 9.5, containing 100 mM sodium chloride and 50 mM magnesium chloride. The protein bands containing carbohydrate are usually visualized in about 10 to 15 min.

The carbohydrate may also be analyzed by digestion with peptide-N-glycosidase F. According to this
procedure the residue is suspended in 14 l of a buffer containing 0.18% \$DS, 18 mM beta-mercaptoethanol, 90
mM phosphate, 3.6 mM EDTA, at pH 8.6, and heated at 100 EC for 3 min. After cooling to room temperature,
the sample is divided into two equal parts. One aliquot is not treated further and serves as a control. The second
fraction is adjusted to about 1% NP-40 detergent followed by 0.2 units of peptide-N-glycosidase F (Boehringer).
Both samples are warmed at 37° C for 2 m and them analyzed by SDS-polyacrylamide gel electrophoresis.

Preferred methods of analysis include those described for the analysis of antibody associated oligosaccharides and described in, for example Worald et al., (1997) Biochem, 36:1370-1380; Sheeley et al. (1997) Anal. Biochem. 247: 102-110 and Cant et al., (1994) Cytotechnology 15:223-228 as well as the references cited therein.

The recovered glycoproteins are purified according to known techniques employed in antibody preparations as described herein. The recovered purified antibodies are analyzed to confirm primary and secondary structure as described herein and in the Figures and Examples. Techniques for the analysis of intact glycoproteins are known in the art (Cant et al., (1994) Cytotechnology 15:223-228; Iwase et al., (1996) J. Biochem. 120:393-397: Sheeley et al., (1997) Analytical Biochemistry, 247:102-110). Typically the structural 10 analysis is followed by functional analysis. As will be appreciated by the skilled artisan the constant domains. are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity and complement mediated cell lysis. The binding site on IgG for CIq, the first component of the complement cascade has been localized to the CH2 domains. Therefore standard analysis such as assays for complement dependent cytotoxicity such as those 15 described for anti CD-20 antibodies are appropriate (Gazzano-Santoro et al., (1997) J. Immunol, Methods 202:163-171). Assays for antigen-mediated aggregation of IgG1, IgG2 and IgG3 initiates complement activation, binding of IgG to the high affinity Fc receptors on monocytes which can stimulate those cells to eliminate the antigen to which the Ig is bound are appropriate for analyzing the functional activity of the recovered glycoprotein as well.

Therapeutic Compositions and Methods

25

Use of the glycoproteins of the present invention as therapeutic compositions is an embodiment of the invention. The uses generally disclosed herein are provided as guidance for the use of the preparations in general. The monoclonal antibody C2B8 (anti-CD20) is provided as an example of a monoclonal antibody developed for cancer treatment as noted above.

Therapeutic formulations of an antibody are prepared for storage by mixing the antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, 16th Edition, Osol., A., Ed., (1980)), in the form of lyophilized cake or aqueous solutions. Pharmaceutically acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; 30 antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterious such as sodium; and/or nonionic surfactants such as TweenIM. 35 Pluronics™, or polyethylene glycol (PEG).

A antibody to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. The formulation ordinarily will be stored in lyophilized form or in solution.

Therapeutic antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or yial having a stopper pierceable by a hypodermic injection needle.

The route of administration is in accord with known methods, e.g., injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained-5 release systems as noted below. The antibody is administered continuously by infusion or by bolus injection.

A cancer patient to be treated with an antibody as an antagonist as disclosed herein may also receive radiation therapy. Alternatively, or in addition, a chemotherapeutic agent may be administered to the patient. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such 10 chemotherapy are also described in Chemotherapy Service Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992). The chemotherapeutic agent may precede, or follow administration of the antagonist or may be given simultaneously therewith. For cancer indications, it may be desirable to also administer antibodies against tumor associated antigens or against angiogenic factors, such as antibodies which bind to HER2 or vascular endothelial factor (VEGF). Alternatively, or in addition, one or more cytokines may be co-administered to the natient.

An effective amount of antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the maximum therapeutic effect. A typical dosage might range from about 1 µg/kg to up to 100 mg/kg of patient body weight, preferably about 10 ug/kg to 10 mg/kg. Typically, the clinician will administer antagonist until 20 a dosage is reached that achieves the desired effect for treatment of the above mentioned disorders. For C2B8 reference is made to International Publication No. WO 94/11026 and EP B 669836, the disclosures of which are specifically incorporated herein by reference.

15

25

35

Routes of administration for the individual or combined therapeutic compositions of the present invention include standard routes, such as, for example, intravenous infusion or bolus injection.

The invention further provides an article of manufacture and kit containing materials useful for the treatment of cancer, for example. The article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition comprising the glycoprotein preparations described herein. The active agent in the composition is the particular glycoprotein such as C2B8. The label 30 on the container indicates that the composition is used for the treatment or prevention of a particular disease or disorder, and may also indicate directions for in vivo, such as those described above.

The kit of the invention comprises the container described above and a second container comprising a buffer. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

The following examples are offered by way of illustration and not by way of limitation. The disclosures of all citations in the specification are expressly incorporated herein by reference.

EXAMPLES EXAMPLE I

Introduction

Substantially homogenous glycoprotein preparations are prepared with reference to the following

5 Examples

Methods

The chimeric monoclonal anti-CD20 antibody (IDEC-C2B8) was produced and purified as described previously (Liu et al., (1987) J. Immunol. 139:5321; Maloney et al., (1994) Blood 84:2457). Other 1gG molecules such as anti-HEIR2 (anti-P185HER2 Carrer et al., (1992) Proc. natl. Acad. Sci. USA 89:4285), anti-VEGF (Kim et al., (1992) Growth Factors 7:33-64), anti-IgE (Presta et al., (1993) J. Immunol. 151:2623) and TNFR-IgG (tumor necrosis factor receptor-IgG; Ashkenazi et al., (1991) Proc. Natl. Acad. Sci. USA 88:10535) were produced by recombinant DNA techniques and expressed in CHO cells. 61,4-galactosyltransferases from human and bovine sources were from Boehringer Mannheim (Indianapolis, IN) and Sigma Chemical Co. (St. Louis, Mo) respectively. UDP-Gal was obtained from Boehringer Mannheim (Indianapolis, IN). Penicillin, streptomycin, glutamine, HEPES, lyophilized rabbit serum and human serum used as the source of complement were purchased from GIBCO-BRL (Grand Island, NY). Fetal bovine serum was purchased from Hydone Laboratories (Logan, UT). Bovine serum albumin (BSA) and Trypan blue were purchased from Sigma Chemical Co. (St. Louis, Mo). Alarnar blue reagent was from Accumed International (Westlake, OH). NAP-5 and Protein A-Sepharose columns were purchased from Pharmscia (Sweden). Sodium cyanoborohydride in tetrahydrofuran was from Aldrich Chemical Co.

IDEC-C2B8

IDEC-C2B8 was formulated at 10 mg/ml in 25 mM sodium citrate, 150 mM sodium chloride, and 0.07 mg/mL Polysorbate 80 at pH 6.5.

EXAMPLE II

25 Enzyme digestion procedure: IgG samples (5-10 mg) were buffer-exchanged into 100 mM citrate-phosphate buffer, pH 5.0, using NAP-5 columns (Pharmacia). β-Galactosidase (40 mU/mg protein, Diplococcus pneumoniae, Boehringer Mannheim) and N-acetyl-β-D-glucosaminidase (40 mU/mg protein, Diplococcus pneumoniae, Boehringer Mannheim or jack bean enzyme from Sigma) were added to 5-10 mg aliquoto of protein and incubated at 37°C for 12-24 hrs. The IgG samples were purified on a Protein A column. The purified protein was subjected to electrospray lonization mass spectrometry, capillary electrophorosis for carbohydrate analysis. The bioactivity was examined by CDC bioassay, binding assay and Clq binding studies.

Figure 1 A, Figure 1B and Figure 1C depict oligosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by capillary electrophoresis with laser-induced fluorescence detection. In Figure 1A C2B8 produced in 400L batch-fed culture produced at least three glycoforms of C2B8. Figure 1B depicts the same C2B8 preparation treated with galactosidase. Figure 1C depicts the preparation treated with both β-galactosidase and N-acetylglucosaminosidase A single G-2 glycoform preparation was obtained.

EXAMPLE III

CIq binding was assessed using the method of Reff et al., (1994) Blood 83:435-45. Briefly, 50µl of wil2 cells were mixed with various amounts of C2B to which various amounts of C3B to which various amounts of

were washed with buffer several times and the amount of C1q bound was measured using florescently labeled anti-C1a antibody.

Figure 2 depicts the binding of C2B8 to C1q. Both G2 and G-2 preparations bound C1q to a greater extent than control samples exhibiting heterogeneous glycoforms.

5

Complement dependent coroloxicity: The CDC bioassay of C2B8 samples was performed using RHBP

(RPMI-1640 supplemented with 0.14 BBSA, 20 mM HEPES (pH 7.2-7.4), 100 IU/ml penicillin and 100 µg/ml

streptomycin. For the assay, 50 µl of 10⁶ cells/ml cell suspension, 50 µl of various concentrations of C2B8 and

50 ml of a 1/5 rabbit complement or human complement dilution were added to flat-bottomed 96-well tissue

culture plates and incubated for 2 h at 37⁶C and 59⁶ CO₂ to facilitate complement-mediated cell lysis. Fifly

microliters of Alamar blue (undiluted, proprietary formulation of Accumed International) was then added and
the incubation continued for another 5 h. The plates were allowed to cool to room temperature for 10 min on
a shaker and the fluorescence was read using a 96-well fluorometer with excitation at 530 nm and emission at
590 nm. Results are expressed in relative fluorescence units (RFU). RFU were plotted against C2B8
concentrations using a 4-parameter curve-fitting program (kaleidaGraph) and the sample concentrations were

15 computed from the standard curve. All C2B8 concentrations shown throughout this report refer to final
concentrations in the wells before the addition of Alamar blue (Gazzano-Santoro (1997) J. Immunol. Meth.
202:163-1711.

Figure 3 depicts the bioactivity of the G2 and G-2 glycoform preparation compared with the heterogenous composition for C2B8 in a rabbit complement lysis assay.

Example IV

GALACTOSYLATION WITH GALACTOSYLTRANSFERASE:

The antibody samples (IDEC-C2B8, anti-HER2, anti-VEGF, anti-HgE and TNFR-HgG), 10 mg in 0.5
ml, were buffer exchanged into 50 mM sodium cacodylate buffer, pH 7.1 (final vol. 1.0 ml), 30 µl each of 100
mM UDP-Gal and 100 mM MnCl₂ were added to the antibody solution. The B1,4-galactosyltransferase (b1,4GT;
lyophilized powder) was reconstituted in 50 mM sodium cacodylate buffer pH 7.1 at a concentration of 1 mUmi.
50 µl of this solution was added to the reaction mixture and incubated at 37°C for 48 hr. The reaction was
stopped by cooling the reaction vial on ice (4°C) for 10 min. The galactosylated antibody was purified on
protein A column.

Example V

30 PURIFICATION OF GALACTOSYLATED ANTIBODY ON PROTEIN-A COLUMN:

The reaction mixture containing galactosylated antibody was applied to a Protein A-Sepharose column.

(S ml). The column was washed with at least 5 column volumes of phosphate buffered saline (pH 7.0) and the bound antibody was cluted with 100 mM citric acid, pH 3.0, which was immediately adjusted to pH 6.5 by adding 500 mM Tris-HCl buffer pH 8.0.

35 Analysis of the N-linked oligosaccharides

20

Release and Labeling of N-linked oligosaccharides

Protein samples (500-1000 µg) were buffer exchanged into 20 mMs sodium phosphate buffer containing 50 mM EDTA and 0.02% (w/v) sodium azide, pH 1.5, using NAP-5 columns (Pharmacila). Five to ten units of recombinant pentide-Ne-Evosidase P (Oxford Ghososvatems/Bochrimer Mannheim) was added to the samnles

and incubated for 15 hours at 37°C. The deglycosylated protein was precipitated by heating at 95°C for 5 minutes and removed by centifugation at 10,000 g for 10 minutes. The supermatant containing the released oligosaccharides was dried in a centrifugal vacuum evaporator and labeled by the addition of 15 μL of 1.9 mM solution of 9-aminopyrene-1,4,6-trisulfonate (APTs, Beckmann) in 15% acetic acid and 5 μL of 1 M sodium 5 cyanoborohydride in tetrahydrofuran. The labeling reaction was carried out for 2 hours at 55°C, diluted in water (0.5 ml) and analyzed by capillary electrophoresis (CE).

Example VI

Capillary Electrophoresis Analysis

CE analysis of the labeled oligosaccharides was performed on a PIACE 5000 CE system (Beckman)
with the polarity reversed, using a coated capillary of 50 mm internal diameter and 20 cm effective length (cCAP,
N-CHO coated capillary, Beckmann). The samples were introduced by pressure injection at 0.5 psi. for 8
seconds and electrophoresis was carried out at a constant voltage of 740 V/cm. The temperature of the capillary
was maintained at 20°C. The separations were monitored on-column with a Beckmann laser-induced
fluorescence detection system using a 3 mW argon-ion laser with an excitation wavelength of 488 nm and
emission bandpass filter at 520 x 10 mm.

Results

30

Figure 4A and Figure 4B depict oligosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by capillary electrophoresis with laser-induced fluorescence detection. In Figure 4A C2B8 produced in 400L both-fed culture produced at least three glycoforms of C2B8. Figure 4B depicts the same C2B8 preparation treated with β1-4 galactosyltransferase according the present invention. A single G2 glycoform preparation was obtained.

Figure 5 depicts analysis of an anti-VEGF monoclonal antibody by capillary electrophoresis. In Figure 5 anti-VEGF produced in CHO cell culture produced at least three glycoforms forming a heterogenous composition. The same anti-VEGF treated with β-1-4 galactosyltransferase according the present invention produced a single G2 glycoform.

Figure 6 depicts analysis of an anti-IgE monoclonal antibody by capillary electrophoresis. In Figure 6 anti-IgE produced in CHO cell culture produced at least three glycoforms forming a heterogenous olligosaccharide population. The same anti-IgE CHO cell composition treated with β -1-4 galactosyltransferase according the present invention produced a single G2 glycoform.

Figure 7 deplcts analysis of an anti-HER2 monoclonal antibody by capillary electrophoresis. In Figure 7 anti-HER2 produced in CHO cell culture produced at least three glycoforms forming a heterogenous oligosaccharide population. The same anti-HER2 CHO composition treated with β -1-4 galactosyltransferase according the present invention produced a single G2 glycoform.

Example V

35 SODIUM DODECYLSULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)

Protein samples were diluted to 1.0 mg/mL into phosphate-buffered saline (PBS). The samples were diluted to 0.2 mg/mL for the silver stained gels and to 0.5 mg/mL for the immunoblots into sample buffer and heated for 3 minutes at 90°C. For reduced samples, the sample buffer contained 80 mM DTT. Samples (10 µL) were loaded onto Integrated Separation Systems (ISS) MiniPlus Sepragels, with a 4-20% acrylamide gradient.

Electrophoresis was performed using the ISS Mini 2 gel apparatus at 30 mA per gel for 60 minutes. Novex Mark12 molecular weight standards were used in the silver stained gels whereas Amersham Rainbow molecular weight standards were used in the gels prepared for immunoblotting.

Silver Stain 5 SDS

SDS PAGE gels were ineubsted overnight in a fixing solution (40% ethanol, 10% acetic acid), washed in water and incubated in incubation solution (30% ethanol, 25% glutaraldehyde, 0.5 M sodium acetate, 10 mM sodium (hiosulfate). The gels were washed again and incubated for 40 minutes in silver nitrate solution (6 mM silver nitrate, 0.01% formaldehyde), washed and developed with two changes of developing solution (0.3 M sodium carbonate, 0.01% formaldehyde). The reaction was stopped by incubating for 10 min in stop solution (40 mM EDTA) and then washed before scanning.

Figure 8 depicts a representative SDS polyacrylamide gel analysis of an anti-CD20 monoclonal antibody under non-reducing conditions. Lane 1 is molecular weight standards, Lane 2 is the G2 glycoform of C2B8; Lane 3 is the C2B8 preparation treated with galactosidase to remove galactose residues from the oligoasaccharides; Lane 4 is the CHO derived C2B8 preparation treated with PNGase-F for the removal of intact oligoasaccharide; Lane 5 is the C2B8 antibody from CHO production; Lane 6 is the CHO derived C2B8 after incubation at 37 C for 24 hours; lane 7 is the CHO derived C2B8 and BSA. The representative gel shows that the integrity of the C2B8 molecule remains instet after treatment with the galactosyltransferase. The G2 glycoform does not disrupt the primary structure of the antibody.

Figure 9 depicts the same material described above analyzed by polyacrylamide gel electrophoresis

20 under reducing conditions. The C2B8 heavy and light chains remain intact.

Example VI

ELECTROTRANSFER AND IMMUNOSTAINING

After SDS-PAGE, the protein was electrotransferred to nitrocellulose (0.2 m, Seleieher and Schuell)
in a NovaBiol Semi-Dry electrotransfer apparatus in transfer buffer (39 mM glycine, 48 mM TRIS, 0.04% SDS,
20% methanol) for 90 minutes at 10 V. After electrotransfer, the aircocellulose sheets were blocked in gelatin
buffer (50 mM TRIS, 150 mM NaCl, 4.3 mM EDTA, 0.05% Triton X-100, and 0.25% fish gelatin). The
immunoblots were probed with an affinity purified goat anti-human [gc (Jackson Laboratories) or goat antiCHOP (IDEC Pharmaeeuticals). Following incubation with the primary antisera the nitrocellulose sheets were
washed with gelatin buffer and then incubated for 90 minutes with a rabbit anti-goat [gc-HRP (JacksonLammanoresearch).* The immunoblots were washed with gelatin buffer and then PBS/Tween 20.
immunoblots were stained with the substrate solution; 3,3-diaminobenzidine tetralydrochloride dihydrate
(DAB), 0.5 mg/mL, nickel ammonium sulfate, 0.3 mg/mL; cobalt chloride, 0.3 mg/mL in PBS with H₂O₂.

Example VII

CIRCULAR DICHROISM SPECTROSCOPY

35

The circular dichroic (CD) spectra of GT treated and untreated CZB8 was obtained on an AVIV 60DS spectropolarimeter. Each sample was dialyzed against 25 mM sodium citrate and 150 mM sodium chloride and then pipetted into a 0.01-cm thermostatted circular cuvette. Each spectrum was the sum of 5 scans from 200 to 250 mm. The spectra were obtained at 20°C. The protein concentration was determined using a A^{0.1%} = 1.7 cm⁻¹ at 280 mm. The mean residue weight ellipticity was calculated from

[Q]MRW = Qohs*(MRW)/ 10 c I

where Q_{obs} is the ellipticity of the sample, MRW is the mean residue weight of the IDEC-C2B8 (108.8), c is the sample concentration in mg/mL, and I is the path length of the cell in cm. The content of the secondary structural elements, α-helix, β-sheet, and non-ordered structure was calculated using the program CONTIN (Provencer and 5 Glockner (1981) Biochem. 20:33-37; Provencer (1982) Comput. Phys. Commun. 27:229-242).

Figure 10A and Figure 10B depict far and near UV CD spectra of C2B8 antibody from CHO culture and the G2 glycoform. As can be concluded from this analysis the G2 glycoform examined by circular dichroism as an indication of secondary structure (Provencer and Glockner (1981), Blochem. 20:33-37) is the same as the heterogenous C2B8 composition.

Example VIII

CULTURE OF WIL2-S CELLS:

10

The human B-lymphoblastoid cell line WIL2-S was obtained from the American Type Culture

Collection (ATCC, Rockville, MD). The cells were grown in RPMI-1640 medium supplemented with 10% heatinactivated (sc⁵0-, 30 min) fetal bovine serum, 2 mM glutamine and 20 mM HEPES, pH 7.2. Cells were cultured

at 37⁹C in a humidified 5% CO₂ incubator.

COMPLEMENT-DEPENDENT CYTOTOXICITY BIOASSAY:

The CDC bioassay of C2B8 samples was performed using RHBP (RPMI-1640 supplemented with 0.1% BSA, 20 mM HEPES (pH 7.2-7.4), 100 IU/ml penicillin and 100 µg/ml streptomycin. For the assay, 50 µl of 10⁶ cells/ml cell suspension, 50 µl of various concentrations of C2B8 and 50 ml of a 15′ rabbit complement or buman complement dilution were added to flat-bottomed 96-well tissue culture plates and incubated for 2 h at 37°C and 5% CO₂ to facilitate complement-mediated cell lysis. Fifty microliters of Alamar blue (undiluted, proprietary formulation of Accumed International) was then added and the incubation continued for another 5 h. The plates were allowed to cool to room temperature for 10 min on a shaker and the fluorescence was read using a 96-well fluorometer with excitation at 530 nm and emission at 590 nm. Returbs are expressed in relative 25 fluorescence units (RFU). RFU were plotted against C2B8 concentrations using a 4-parameter curve-fitting program (kaleidaGraph) and the sample concentrations were computed for the standard curve. All C2B8 concentrations shown throughout this report refer to final concentrations in the wells before the addition of Alamar blue (Gazzano-Sentoro (1997). Immunol, Meth. 202:163-171).

Figure 11 depicts the bioactivity of the G2 glycoform preparation compared with the heterogenous

30 composition for C2B8 in a rabbit complement lysis assay.

Figure 12 depicts the correlation of bioactivity and galactose content in the G2 glycoform. The G2 glycoform preparation was at least 1.5 times more active in this assay than that produced under twoical cell culture conditions.

WHAT IS CLAIMED IS:

3.

5

25

35

A composition comprising glycoprotein wherein at least one glycoprotein is a glycoprotein
having at least one CH2 domain and the composition is substantially free of the glycoprotein having at least one
CH2 domain and having an N-linked G1, G0, or G-1 oligosaccharide in its CH2 domain.

- The composition of claim 1 comprising an antibody glycoprotein.
 - The composition of claim 2 wherein the antibody glycoprotein is a monoclonal antibody.
 - 4. The composition of claim 3 wherein the monoclonal antibody is an IgG.
 - The composition of claim 4 wherein the lgG is human IgG.
- 6. The composition of claim 5 wherein the monoclonal antibody is selected from the group 10 consisting of an anti-CD20 specific monoclonal antibody, an anti-HER2 specific monoclonal antibody, and anti-
 - VEGF specific monoclonal antibody, and an anti-IgE specific monoclonal antibody.
 - 7. The composition of claim 6 wherein the monoclonal antibody is an anti-CD20 antibody.
 - 8. The composition of claim 1 comprising an immunoadhesin glycoprotein.
- The composition of claim 8 wherein the immunoadhesin glycoprotein is a tumor necrosis
 factor-immunoglobulin GI chimera.
- The composition of claim 1 wherein the composition is further substantially free of a glycoprotein having an N-linked G2 oligosaccharide in the CH2 domain.
 - 11. The composition of claim 10 comprising an antibody glycoprotein.
 - 12. The composition of claim 11 wherein the antibody glycoprotein is a monoclonal antibody.
- 20 13. The composition of claim 12 wherein the antibody is an IgG.
 - 14. The composition of claim 13 wherein the IgG is human IgG1.
 - 15. The composition of claim 14 wherein the monoclonal antibody is selected from the group consisting of an anti-CD20 specific monoclonal antibody, and anti-UR22 specific monoclonal antibody, and anti-VEGF specific monoclonal antibody. and an anti-IEE specific monoclonal antibody.
 - The composition of claim 15 wherein the monoclonal antibody is an anti-CD20 antibody.
 - 17. The composition of claim 10 wherein the glycoprotein is an immunoadhesin.
 - The composition of claim 17 wherein the immunoadhesin is a tumor necrosis factorimmunoglobulin G1 chimera.
 - 19. The composition of claim 10 wherein the glycoprotein is an antibody-immunoadhesin chimera.
- 30 20. The composition of claim 1 wherein the composition is further substantially free of the glycoprotein having an N-linked G-2 oligosaccharide in the CH2 domain.
 - A method of producing the composition of claim 20 comprising the steps of reacting in an aqueous buffered solution at a temperature of about 25-40° C;
 - a) a metal salt at a concentration of about 5 mM to about 25 mM;
 - b) an activated galactose at a concentration of about 5 mM to about 50 mM;
 - c) a galactosyltransferase at a concentration of about 1 mUnit/ml to about 100 mUnit/ml;
 - d) a substrate glycoprotein; and recovering the glycoprotein.

 The method of claim 21 wherein the metal salt is selected from the group consisting of Mn2++, Ca2++, and Ba2++.

- 23. The method of claim 22 wherein the activated galactose is uridine diphosphate-galactose (UDP-galactose).
- 5 24. The method of claim 23 wherein the galactosyl transferase is a mammalian β 1-4, galactosyl transferase
 - 25. The method of claim 24 wherein the reaction temperature is about 37° C, the metal salt is Mn2++ at a concentration of about 5 mM, the UDP-galactose concentration is about 5mM and the β 1-4 salactose/ transferace concentration is about 1 mUnit/ml.
 - The method of claim 25 wherein the glycoprotein is an antibody.
 - 27. The method of claim 26 wherein the antibody is an IgG.
 - 28. The method of claim 27 wherein the IgG is human IgG1.
 - 29. The method of claim 28 wherein the monoclonal antibody is selected from the group consisting of an anti-CD20 specific monoclonal antibody, and anti-HER2 specific monoclonal antibody, and anti-VEGF specific monoclonal antibody, and an anti-IgE specific monoclonal antibody.
 - 30. The method of claim 29 wherein the glycoprotein is an immunoadhesin.
 - 31. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 1.
- 32. A method for the treatment of a disease state comprising administering to a mammal in need thereof 20 a therapeutically effective dose of the composition of claim 10.
- 33. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 6.
 - 34. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 16.
- 25 35. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.
 - 36. A pharmaceutical composition comprising the composition of claim 10 and a pharmaceutically acceptable carrier.
- A pharmaceutical composition comprising the composition of claim 6 and a pharmaceutically
 acceptable carrier.
 - 38. A pharmaceutical composition comprising the composition of claim 16 and a pharmaceutically acceptable carrier.
 - A pharmaceutical composition comprising the composition of claim 7 and a pharmaceutically acceptable carrier.
- 35 40. A pharmaceutical composition comprising the composition of claim 17 and a pharmaceutically accentable carrier.
 - 41. An article of manufacture, comprising:
 - a container;

10

a label on said container; and

the composition of claim 1 contained within said container.

42. An article of manufacture, comprising:

a container:

a label on said container; and

- 5 the composition of claim 10 contained within said container.
 - 43. The article of claim 41 wherein the label on the container indicates that the composition can be used for the treatment of cancer.
 - 44. The article of claim 42 wherein the label on the container indicates that the composition can be used for the treatment of cancer.

Before enzyme treatment.




FIG. 1A

After treatment with 8-galactosidase.




FIG. 1B

After treatment with B-galactosidase and N-acetyl B-D-glucosaminidase.





FIG. 1C

SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)







FIG. 4A




SUBSTITUTE SHEET (RULE 26)







SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)






SUBSTITUTE SHEET (RULE 26)







SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

Interr. net Application No PCT/US 98/21925

IPC 6	FICATION OF SUBJECT MATTER A61K39/395 C07K16/00 C12P21/0	00		
According to	internetionel Petent Classification (IPC) or to both national classifica-	ntion and IPC		
B. FIELDS SEARCHED				
	cumentation seerched (classification system followed by classification CO7K	on symbols)		
Documental	ion searched other than minimum documentation to the extent that a	ach documents are included in the fields so	eerched	
Electronic d	eta base consulted during the International search (name of data ber	se and, where practical, search terms used)	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the reli	evant passages	Relevent to cleim No.	
X	KLAMA K ET AL: "The abnormalities in the glycosylation of IgG" REUMATOLOGIA, vol. 34, no. 1, 1996, pages 26-30,		1-5, 10-14,20	
γ ,	XP002081302 see page 26, line 1 - page 27, last line		1–44	
X	LIFELY M R (REPRINT) ET AL: "Glycosylation and biological-activity of CAMPATH-1H expressed in different cell-lines and grown under different culture conditions" GLYCOBIOLORY, (DEC 1995) VOL. 5, NO. 8,		1-5, 10-14,20	
Y	PP. 813-822. ISSN: 0959-6658., XF see introduction and discussion		1–44	
X Fund	her documents ere listed in the continuation of box C.	Patent family members are listed	in annex.	
** Specials categories of clast documents: **A' document defining the general state of the art which is not class of comment defining the general state of the art which is not class of class of comments and comments of class of			islaimed Invention to considered to current is later alone staimed invention are ventire step when the re other such docu- us to a person skilled femily	
10 March 1999		0 7. 04. 99		
Name and I	nalling address of the ISA Europeen Patent Office, P.B. 5818 Patentisen 2 NL - 2280 HV Filiswijk Tei. (+31-70) 340-2040, Tx. 31 651 epo ni,	Authorized officer Mull len-Thomalla	r	

Interr 1al Application No PCT/US 98/21925

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category * | Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WRIGHT A ET AL: "Effect of altered CH2 1-5. -associated carbohydrate structure on the 10-14,20 functional properties and in vivo fate of chimeric mouse-human immunoclobulin 61. JOURNAL OF EXPERIMENTAL MEDICINE, (1994) SEP 1) 180 (3) 1087-96. JOURNAL CODE: I2V. ISSN: 0022-1007., XP000676306 United States see abstract; page 1087, column 1, line 1 1-44 to page 1088, column 2, second paragraph: discussion X BOYD P N ET AL: "The effect of the removal of sialic acid, galactose and 10-14.20 total carbohydrate on the functional activity of CAMPATH-1H" MOLECULAR IMMUNOLOGY, vol. 32, no. 17/18, 1995, pages 1311-1318, XP000676340 cited in the application see abstract and discussion 1-44 Y UMANA P ET AL: "A mathematical model of N 1-44 - linked glycoform biosynthesis* BIOTECHNOLOGY AND BIOENGINEERING, (20 SEP 1997) VOL. 55, NO. 6, PP. 890-908. PUBLISHER: JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012, ISSN: 0006-3592., XP002096119 see abstract, introduction, figures 1 and 2: discussion DWEK R A ET AL: "Glycobiology: 'the function of sugar in the IgG molecule'." JOURNAL OF ANATOMY, (1995 OCT) 187 (PT 2) 279-92. JOURNAL CODE: HBB. ISSN: 0021-8782., XP002096120 ENGLAND: United Kingdom see abstract, introduction; page 282, column 1, last paragraph to page 284, column 1, first paragraph; A WEITZHANDLER M ET AL: "Analysis of carbohydrates on IgG preparations. JOURNAL OF PHARMACEUTICAL SCIENCES, (1994 DEC) 83 (12) 1670-5. JOURNAL CODE: JO7. ISSN: 0022-3549., XP002096121 United States cited in the application see the whole document -/--

Form PCT/ISA/210 Igentinuation of second shoeti (July 1992)

Interr net Application No PCT/US 98/21925

C.(Continuation) DOCUMENTS CONSIDERED TO BE BELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Α JEFFERSIS ET AL .: "Glycosylation of antibody molecules: Structural and functional significance. CHEMICAL IMMUNOLOGY, vol. 65, 1997, pages 111-128, XP002096122 cited in the application see the whole document Α WRIGHT ET AL.: "Effect of glycosylation on antibody funtion: implications for genetic engineering." TIBTECH, vol. 15, 1997, pages 26-32, XP004016809 cited in the application see the whole document Α WORMALD ET AL.: "Variations in oligosaccharide-Protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides." BIOCHEMISTRY, vol. 36, 1997, pages 1370-1380, XP002096123 cited in the application see the whole document X.P RAJU ET AL: "Biological significance and 1.2.35 structural features of immunoglobulin glycoforms" BOOK OF ABSTRACTS. ACS NATIONAL MEETING. 29 April 1998, page COMPLETE 1 XP002081304 see abstract

,

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

International application No. PCT/US 98/21925

Box i Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)			
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
Claims Nos.: Claim 1 (partially) because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210			
Claims Nox.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box ii Observations where unity of invention is lacking (Continuation of item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows:			
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.			
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
As only some of the required additional search fees were timely paid by the applicant, this Informational Search Report covers only those claims for which fees were paid, specifically claims Nos.:			
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims, it is covered by claims. Noz.:			
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: claim 1 (partially)

The subject-matter of claim I which is defined mainly in terms of megative functional features is formulated in such an unclear manner that said claim could only be searched partially. In accordance with the definition of the invention given in the description, the subject-matter of claim I as searched has been interpreted as relating to a glycoprotein composition whereby at least one glycoprotein is a glycoprotein having at least one CHZ domain of the heavy chain immunoglobulin constant region, whereby said CHZ domain is substantially free of N-linked GI, 60 ir G-1 oligosaccharide.

Therapeutic antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The route of administration is in accord with known methods, e.g., injection or infusion by intravenous. intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained-5 release systems as noted below. The antibody is administered continuously by infusion or by bolus injection.

A cancer patient to be treated with an antibody as an antagonist as disclosed herein may also receive radiation therapy. Alternatively, or in addition, a chemotherapeutic agent may be administered to the patient. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such 10 chemotherapy are also described in Chemotherapy Service Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992). The chemotherapeutic agent may precede, or follow administration of the antagonist or may be given simultaneously therewith. For cancer indications, it may be desirable to also administer antibodies against tumor associated antigens or against angiogenic factors, such as antibodies which bind to HER2 or vascular endothelial factor (VEGF). Alternatively, or in addition, one or more cytokines may be co-administered to the parient.

An effective amount of antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the maximum therapeutic effect. A typical dosage might range from about 1 µg/kg to up to 100 mg/kg of patient body weight, preferably about 10 ug/kg to 10 mg/kg. Typically, the clinician will administer antagonist until 20 a dosage is reached that achieves the desired effect for treatment of the above mentioned disorders. For C2B8 reference is made to International Publication No. WO 94/11026 and EP B 669836, the disclosures of which are specifically incorporated herein by reference.

Routes of administration for the individual or combined therapeutic compositions of the present invention include standard routes, such as, for example, intravenous infusion or bolus injection.

25

35

The invention further provides an article of manufacture and kit containing materials useful for the treatment of cancer, for example. The article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition comprising the glycoprotein preparations described herein. The active agent in the composition is the particular glycoprotein such as C2B8. The label 30 on the container indicates that the composition is used for the treatment or prevention of a particular disease or disorder, and may also indicate directions for in vivo, such as those described above.

The kit of the invention comprises the container described above and a second container comprising a buffer. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

The following examples are offered by way of illustration and not by way of limitation. The disclosures of all citations in the specification are expressly incorporated herein by reference.

EXAMPLES EXAMPLE I

Introduction

Substantially homogenous glycoprotein preparations are prepared with reference to the following

5 Examples

Methods

The chimeric monoclonal anti-CD20 antibody (IDEC-C2B8) was produced and purified as described previously (Liu et al., (1987) J. Immunol. 139:3521; Maloney et al., (1994) Blood 84:2457). Other IgG molecules such as anti-HER2 (anti-P185HER2 Carter et al., (1992) Proc., nad. Acad. Sci. USA, 83:4285), anti-10 VEGF (Kim et al., (1992) Growth Factors 7:53-64), anti-IgE (Presta et al., (1993) J. Immunol. 151:2623) and TNFR-IgG (tumor necrosis factor receptor-IgG; Ashkenazi et al., (1991) Proc. Natl. Acad. Sci. USA, 88:10335) were produced by recombinant DNA techniques and expressed in CHO cells. β1.4-galactosyltransferases from human and bovine sources were from Boehringer Mannheim (Indianapolis, IN) and Sigma Chemical Co. (St. Louis, Mo) respectively, UDP-Gal was obtained from Boehringer Mannheim (Indianapolis, IN). Penicillin, 15 streptomycin, glutamine, HEPES, lyophilized rabbit serum and human serum used as the source of complement were purchased from GIBCO-GRL (Grand Island, NY). Fetal bovine serum was purchased from Hyelone Laboratories (Logan, UT). Bovine serum albumin (BSA) and Trypan blue were purchased from Sigma Chemical Co. (St. Louis, Mo). Alamar blue reagent was from Accumed International (Westlake, OE). NAP-5 and Protein A-Sepharose columns were purchased from Pharmacia (Sweden). Sodium cyanoborohydride in tetrahydrofuran was from Aldrich Chemical Co.

IDEC-C2B8

IDEC-C2B8 was formulated at 10 mg/ml in 25 mM sodium citrate, 150 mM sodium chloride, and 0.07 mg/mL Polysorbate 80 at pH 6.5.

EXAMPLE II

25 Eazyme digestion procedure: IgG samples (5-10 mg) were buffer-exchanged into 100 mM citrate-phosphate buffer, pH 5.0, using NAP-5 columns (Pharmacia). β-Galactosidase (40 mU/mg protein, Diplococcus pneumoniae, Bochringer Mannheim) and N-acetyl-β-D-glucosuminidase (40 mU/mg protein, Diplococcus pneumoniae, Bochringer Mannheim or jack bean enzyme from Sigma) were added to 5-10 mg aliquots of protein and incubated at 37°C for 12-24 hrs. The IgG samples were purified on a Protein A column. The purified op protein was subjected to electrospray ionization mass spectrometry, capillary electrophoresis for carbohydrate analysis. The bioactivity was examined by CDC bioassay, binding assay and CI a binding studies.

Figure 1 A, Figure 1B and Figure 1C depict ofigosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by expillary electrophoresis with laser-induced fluorescence detection. In Figure 1A C2B8 produced in 400L batch-fed culture produced at least three glycoforms of C2B8. Figure 1B depicts the same 35 C2B8 preparation treated with galactosidase. Figure 1C depicts the preparation treated with both β-galactosidase and N-acetylglucosaminosidase A single G-2 glycoform preparation was obtained.

EXAMPLE III

Clq binding was assessed using the method of Reff et al., (1994) Blood 83:435-45. Briefly, 50µl of wil2 cells were mixed with various amounts of C2B8 to which various amounts of Clq were added. The cells

were washed with buffer several times and the amount of C1q bound was measured using florescently labeled

Figure 2 depicts the binding of C2B8 to C1q. Both G2 and G-2 preparations bound C1q to a greater extent than control samples exhibiting heterogeneous glycoforms.

Complement dependent cytotoxicity: The CDC bioassay of C2B8 samples was performed using RHBP (RPMI-1640 supplemented with 0.1% BSA, 20 mM HEPES (pH 7.2-7.4), 100 IU/ml penicillin and 100 ug/ml streptomycin. For the assay, 50 μ l of 10^6 cells/ml cell suspension, 50 μ l of various concentrations of C2B8 and 50 ml of a 1/5 rabbit complement or human complement dilution were added to flat-bottomed 96-well tissue culture plates and incubated for 2 h at 370C and 5% CO₂ to facilitate complement-mediated cell lysis. Fifty 10 microliters of Alamar blue (undiluted, proprietary formulation of Accumed International) was then added and the incubation continued for another 5 h. The plates were allowed to cool to room temperature for 10 min on a shaker and the fluorescence was read using a 96-well fluorometer with excitation at 530 nm and emission at 590 nm. Results are expressed in relative fluorescence units (RFU). RFU were plotted against C2B8 concentrations using a 4-parameter curve-fitting program (kaleidaGraph) and the sample concentrations were 15 computed from the standard curve, All C2B8 concentrations shown throughout this report refer to final concentrations in the wells before the addition of Alamar blue (Gazzano-Santoro (1997) J. Immunol. Meth. 202:163-171).

Figure 3 depicts the bioactivity of the G2 and G-2 glycoform preparation compared with the heterogenous composition for C2B8 in a rabbit complement lysis assay.

Example IV

20

The antibody samples (IDEC-C2B8, anti-HER2, anti-VEGF, anti-IgE and TNFR-IgG), 10 mg in 0.5

GALACTOSYLATION WITH GALACTOSYLTRANSFERASE:

mi, were buffer exchanged into 50 mM sodium cacodylate buffer, pH 7.1 (final vol. 1.0 ml), 50 µl each of 100 mM UDP-Gal and 100 mM MnCL, were added to the antibody solution. The \$1.4-galactosyltransferase (b1.4GT: 25 Ivophilized powder) was reconstituted in 50 mM sodium cacodylate buffer pH 7.1 at a concentration of 1 mU/mL 50 ul of this solution was added to the reaction mixture and incubated at 370C for 48 hr. The reaction was stopped by cooling the reaction vial on ice $(4^{\circ}C)$ for 10 min. The galactosylated antibody was purified on protein A column.

Example V

30 PURIFICATION OF GALACTOSYLATED ANTIBODY ON PROTEIN-A COLUMN:

The reaction mixture containing galactosylated antibody was applied to a Protein A-Sepharose column (5 ml). The column was washed with at least 5 column volumes of phosphate buffered saline (pH 7.0) and the bound antibody was eluted with 100 mM citric acid, pH 3.0, which was immediately adjusted to pH 6.5 by adding 500 mM Tris-HCl buffer pH 8.0.

35 Analysis of the N-linked oligosaccharides

Release and Labeling of N-linked oligosaccharides

Protein samples (500-1000 µg) were buffer exchanged into 20 mM sodium phosphate buffer containing 50 mM EDTA and 0.02% (w/v) sodium azide, pH 7.5, using NAP-5 columns (Pharmacia). Five to ten units of recombinant peptide-N-glycosidase F (Oxford Glycosystems/Boehringer Mannheim) was added to the samples

and incubated for 15 hours at 37°C. The deglycosylated protein was precipitated by heating at 95°C for 5 minutes and removed by centrifugation at 10,000 g for 10 minutes. The supermatant containing the released oligosaccharides was dried in a centrifugal vacuum evaporator and labeled by the addition of 15 μL of 1.9 mM solution of 9-minopyrene-1,4,6-trisulfonate (APTS, Beckmann) in 15% acetic acid and 5 μL of 1 M sodium 5 cyanoborohydride in tetrahydrofuran. The labeling reaction was carried out for 2 hours at 55°C, diluted in water (0.5 ml) and analyzed by capillary electrophoresis (CE).

Example VI

Capillary Electrophoresis Analysis

CE analysis of the labeled oligosaecharides was performed on a PIACE 5000 CE system (Beckman)
with the polarity reversed, using a costed capillary of 50 mm internal diameter and 20 cm effective length (eCAP,
N-CHO coated capillary, Beckmann). The samples were introduced by pressure injection at 0.5 psi. for 8
seconds and electrophoresis was carried out at a constant voltage of 740 V/cm. The temperature of the capillary
was maintained at 20°C. The separations were monitored on-column with a Beckmann laser-induced
fluorescence detection system using a 3 mW argon-ion laser with an excitation wavelength of 488 nm and
emission bandpass filter at 520 x 10 nm.

Results

30

Figure 4A and Figure 4B depict oligosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by capillary electrophoresis with laser-induced fluorescence detection. In Figure 4A C2B8 produced in 400L batch-fed culture produced at least three glycoforms of C2B8. Figure 4B depicts the same C2B8 preparation treated with β1-4 galactosyltransferase according the present invention. A single C2 glycoform preparation was obtained.

Figure 5 depicts analysis of an anti-VEGF monoclonal antibody by capillary electrophoresis. In Figure 5 anti-VEGF produced in CHO cell culture produced at least three glycoforms forming a heterogenous composition. The same anti-VEGF treated with β-1-4 galactosyltransferase according the present invention produced a sinele G2 elycoform.

Figure 6 depicts analysis of an anti-IgE monoclonal antibody by capillary electrophoresis. In Figure 6 anti-IgE produced in CHO cell culture produced at least three glycoforms forming a heterogenous oligosaccharide population. The same anti-IgE CHO cell composition treated with β -1-4 galactosyltransferase according the present invention produced a single G2 glycoform.

Figure 7 depicts analysis of an anti-HER2 monoclonal antibody by capillary electrophoresis. In Figure 7 anti-HER2 produced in CHO cell culture produced at least three glycoforms forming a heterogenous oligosaccharide population. The same anti-HER2 CHO composition treated with β -I-4 galactosyltransferase according the present invention produced a single G2 glycoform.

Example V

35 SODIUM DODECYLSULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)

Protein samples were diluted to 1,0 mg/mL into phosphate-buffered saline (PBS). The samples were diluted to 0.2 mg/mL for the silver stained gels and to 0.5 mg/mL for the immunoblots into sample buffer and heated for 3 minutes at 90°C. For reduced samples, the sample buffer contained 80 mM DTT. Samples (10 µL) were loaded onto Integrated Senaration Systems (TSS) MiniPlus Separaelis, with a 4-20% servlamide gradient.

Electrophoresis was performed using the ISS Mini 2 gel apparatus at 30 mA per gel for 60 minutes. Novex Mark 12 molecular weight standards were used in the silver stained gels whereas Amersham Rainbow molecular weight standards were used in the gels prepared for immunoblotting.

Silver Stain

5

35

SDS PAGE gels were incubated overnight in a fixing solution (40% ethanol, 10% acetic acid), washed in water and incubated in incubation solution (30% ethanol, 25% glutaraldehyde, 0.5 M sodjum acetate, 10 mM sodium thiosulfate). The gels were washed again and incubated for 40 minutes in silver nitrate solution (6 mM silver nitrate, 0.01% formaldehyde), washed and developed with two changes of developing solution (0.3 M sodium carbonate, 0.01% formaldehyde). The reaction was stopped by incubating for 10 min in stop solution 10 (40 mM EDTA) and then washed before scanning.

Figure 8 depicts a representative SDS polyacrylamide gel analysis of an anti-CD20 monoclonal antibody under non-reducing conditions. Lane 1 is molecular weight standards, Lane 2 is the G2 glycoform of C2B8; Lane 3 is the C2B8 preparation treated with galactosidase to remove galactose residues from the oligosaccharides; Lane 4 is the CHO derived C2B8 preparation treated with PNGase-F for the removal of intact 15 oligosaccharide: Lane 5 is the C2B8 antibody from CHO production; Lane 6 is the CHO derived C2B8 after incubation at 37 C for 24 hours: Jane 7 is the CHO derived C2B8 and BSA. The representative gel shows that the integrity of the C2B8 molecule remains intact after treatment with the galactosyltransferase. The G2 glycoform does not disrupt the primary structure of the antibody.

Figure 9 depicts the same material described above analyzed by polyacrylamide gel electrophoresis 20 under reducing conditions. The C2B8 heavy and light chains remain intact.

Example VI

ELECTROTRANSFER AND IMMUNOSTAINING

After SDS-PAGE, the protein was electrotransferred to nitrocellulose (0.2 m, Scleicher and Schuell) in a NovaBlot Semi-Dry electrogransfer apparatus in transfer buffer (39 mM glycine, 48 mM TRIS, 0.04% SDS, 20% methanol) for 90 minutes at 10 V. After electrotransfer, the nitrocellulose sheets were blocked in gelatin buffer (50 mM TRIS, 150 mM NaCl, 4.3 mM EDTA, 0.05% Triton X-100, and 0.25% fish gelatin). The immunoblots were probed with an affinity purified goat anti-human IgG (Jackson Laboratories) or goat anti-CHOP (IDEC Pharmaceuticals). Following incubation with the primary antisers the nitrocellulose sheets were washed with gelatin buffer and then incubated for 90 minutes with a rabbit anti-goat IgG-HRP (Jackson-30 Immunoresearch). The immunoblots were washed with gelatin buffer and then PBS/Tween 20. The immunoblots were stained with the substrate solution; 3,3'-diaminobenzidine tetrahydrochloride dihydrate (DAB), 0.5 mg/mL, nickel ammonium sulfate, 0.3 mg/mL; cobalt chloride, 0.3 mg/mL in PBS with H2O2. Example VII

CIRCULAR DICHROISM SPECTROSCOPY

The circular dichroic (CD) spectra of GT treated and untreated C2B8 was obtained on an AVIV 60DS spectropolarimeter. Each sample was dialyzed against 25 mM sodium citrate and 150 mM sodium chloride and then pipetted into a 0.01-cm thermostatted circular cuvette. Each spectrum was the sum of 5 scans from 200 to 250 nm. The spectra were obtained at 20°C. The protein concentration was determined using a A^{0.1%} = 1.7 cm⁻¹ 1 at 280 nm. The mean residue weight ellipticity was calculated from

 $[Q]_{MRW} = Q_{obs}*(MRW)/10 c 1$

where Q_{obs} is the ellipticity of the sample, MRW is the mean residue weight of the IDEC-C2B8 (108.8), ε is the sample concentration in mg/mL, and I is the path length of the cell in cm. The content of the secondary structural elements, α-helix, β-sheet, and non-ordered structure was calculated using the program CONTIN (Provencer and 5 Glockner (1981) Biochem. 20:33-37; Provencer (1982) Comput. Phys. Commun. 27:229-242.

Figure 10A and Figure 10B depict far and near UV CD spectra of C2B8 antibody from CHO culture and the G2 glycoform. As can be concluded from this analysis the G2 glycoform examined by circular dichroism as an indication of secondary structure (Provencer and Glockner (1981), Biochem. 20:33-37) is the same as the heterogenous C2B8 composition.

Example VIII

CULTURE OF WIL2-S CELLS:

10

The human B-lymphoblastoid cell line WIL2-S was obtained from the American Type Culture
Collection (ATCC, Rockville, MD). The cells were grown in RPMI-1640 medium supplemented with 10% heatinactivated (56⁶C, 30 min) fetal bovine serum, 2 mM glutamine and 20 mM HEPES, pH7.2. Cells were cultured
at 37⁶C in a humidified 5% CO₂ (neubator.

COMPLEMENT-DEPENDENT CYTOTOXICITY BIOASSAY:

The CDC bioassay of C2B8 samples was performed using RHBP (RPMI-1640 supplemented with 0.1% BSA, 20 mM HEPFS (QH 7.2-7.4), 100 IL/ml penicillia and 100 µg/ml streptomycin. For the assay, 50 µ for 10⁶ cella/ml cell suspension, 50 µ of various concentrations of C2B8 and 50 ml of a 1/5 rabbit complement on human complement dilution were added to flat-bottomed 96-well tissue culture plates and incubated for 2 h at 37°C and 5% CO₂ to facilitate complement-mediated cell lysis. Fifty microliters of Alamar blue (undiluted, proprietary formulation of Accumed International) was then added and the incubation continued for another 5 h. The plates were allowed to cool to room temperature for 10 min on a shaker and the fluorescence was read using a 96-well fluorometer with excitation at 530 nm and emission at 590 nm. Results are expressed in relative 55 fluorescence units (RFU). RFU were plotted against C2B8 concentrations using a 4-parameter curve-fitting program (kaleida/Graph) and the sample concentrations were computed for the standard curve. All C2B8 concentrations shown throughout this report refer to final concentrations in the wells before the addition of Alamar blue (Gazzano-Santore (1997). Immunol, Meth. 202:163-171).

Figure 11 depicts the bioactivity of the G2 glycoform preparation compared with the heterogenous composition for C2B8 in a rabbit complement lysis assay.

Figure 12 depicts the correlation of bioactivity and galactose content in the G2 glycoform. The G2 glycoform preparation was at least 1.5 times more active in this assay than that produced under twical cell culture conditions.

WHAT IS CLAIMED IS:

20

25

35

 A composition comprising glycoprotein wherein at least one glycoprotein is a glycoprotein having at least one CH2 domain and the composition is substantially free of the glycoprotein having at least one CH2 domain and having an N-linked G1, G0, or G-1 oligosaccharide in its CH2 domain.

- The composition of claim 1 comprising an antibody glycoprotein.
 - 3. The composition of claim 2 wherein the antibody glycoprotein is a monoclonal antibody.
 - The composition of claim 3 wherein the monoclonal antibody is an IgG.
 - The composition of claim 4 wherein the IgG is human IgG₁.
- The composition of claim 8 wherein the monoclonal antibody is selected from the group
 of consisting of an anti-CD20 specific monoclonal antibody, and anti-HER2 specific monoclonal antibody, and antiVBGF specific monoclonal antibody. and an anti-LE specific monoclonal antibody.
 - The composition of claim 6 wherein the monoclonal antibody is an anti-CD20 antibody.
 - 8. The composition of claim 1 comprising an immunoadhesin glycoprotein.
- The composition of claim 8 wherein the immunoadhesin glycoprotein is a tumor necrosis
 factor-immunoglobulin G1 chimera.
- The composition of claim 1 wherein the composition is further substantially free of a giveoprotein having an N-linked G2 oligosaccharide in the CH2 domain.
 - 11. The composition of claim 10 comprising an antibody glycoprotein.
 - 12. The composition of claim 11 wherein the antibody glycoprotein is a monoclonal antibody.
 - The composition of claim 12 wherein the antibody is an IgG.
 - 14. The composition of claim 13 wherein the IgG is human IgG1.
 - 15. The composition of claim 14 wherein the monoclonal antibody is selected from the group consisting of an anti-CD20 specific monoclonal antibody, and anti-HER2 specific monoclonal antibody, and an anti-LEE specific monoclonal antibody, and an anti-LEE specific monoclonal antibody.
 - The composition of claim 15 wherein the monoclonal antibody is an anti-CD20 antibody.
 - 17. The composition of claim 10 wherein the glycoprotein is an immunoadhesin.
 - The composition of claim 17 wherein the immunoadhesin is a tumor necrosis factorimmunoglobulin GI chimera.
 - 19. The composition of claim 10 wherein the glycoprotein is an antibody-immunoadhesin chimera,
- 30 20. The composition of claim 1 wherein the composition is further substantially free of the glycoprotein having an N-linked G-2 oligosaccharide in the CH2 domain.
 - A method of producing the composition of claim 20 comprising the steps of reacting in an
 agueous buffered solution at a temperature of about 25-40° C:
 - a) a metal salt at a concentration of about 5 mM to about 25 mM;
 - b) an activated galactose at a concentration of about 5 mM to about 50 mM;
 - c) a galactosyltransferase at a concentration of about 1 mUnit/m1 to about 100 mUnit/m1;
 - d) a substrate glycoprotein; and recovering the glycoprotein.

 The method of claim 21 wherein the metal salt is selected from the group consisting of Mn2++, Ca2++, and Ba2++.

- 23. The method of claim 22 wherein the activated galactose is uridine diphosphate-galactose (UDP-galactose).
- 5 24. The method of claim 23 wherein the galactosyl transferase is a mammalian β1-4, galactosyl transferase.
 - 25. The method of claim 24 wherein the reaction temperature is about 37° c, the metal salt is Ma2++ at a concentration of about 5 mM, the UDP-galactose concentration is about 5mM and the β 1-4 salactose/ transferase concentration is about 1 mUnit/ml.
 - The method of claim 25 wherein the glycoprotein is an antibody.
 - 27. The method of claim 26 wherein the antibody is an IgG.
 - 28. The method of claim 27 wherein the IgG is human IgG1.
- The method of claim 28 wherein the monoclonal antibody is selected from the group consisting
 of an anti-CD20 specific monoclonal antibody, and anti-HER2 specific monoclonal antibody, and anti-VEGF
 specific monoclonal antibody, and an anti-LES specific monoclonal antibody.
 - The method of claim 29 wherein the glycoprotein is an immunoadhesin.
 - 31. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 1.
- 32. A method for the treatment of a disease state comprising administering to a mammal in need thereof
 a therapeutically effective dose of the composition of claim 10.
 - 33. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 6.
 - 34. A method for the treatment of a disease state comprising administering to a mammal in need thereof a therapeutically effective dose of the composition of claim 16.
- 25 35. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.
 - 36. A pharmaceutical composition comprising the composition of claim 10 and a pharmaceutically acceptable carrier.
- 37. A pharmaceutical composition comprising the composition of claim 6 and a pharmaceutically
 30 acceptable carrier.
 - A pharmaceutical composition comprising the composition of claim 16 and a pharmaceutically acceptable carrier.
 - A pharmaceutical composition comprising the composition of claim 7 and a pharmaceutically acceptable carrier.
- 40. A pharmaceutical composition comprising the composition of claim 17 and a pharmaceutically acceptable carrier.
 - 41. An article of manufacture, comprising:
 - a container:

10

a label on said container; and

the composition of claim 1 contained within said container.

42. An article of manufacture, comprising:

a container:

5

a label on said container; and

- the composition of claim 10 contained within said container.
- 43. The article of claim 41 wherein the label on the container indicates that the composition can be used for the treatment of cancer.
- 44. The article of claim 42 wherein the label on the container indicates that the composition can be used for the treatment of cancer.

Before enzyme treatment.




FIG. 1A

After treatment with B-galactosidase.




FIG. 1B

After treatment with B-galactosidase and N-acetyl B-D-glucosaminidase.






FIG. 1C

SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)


4/12


FIG. 4A




SUBSTITUTE SHEET (RULE 26)


5/12






SUBSTITUTE SHEET (RULE 26)






SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)







SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

inters. nai Application N

		101700 30721325		
IPC 6	FICATION OF SUBJECT MATTER A61K39/395 C07K16/00 C12P21/00			
According to International Patent Classification (IPC) or to both netional classification and IPC				
	SEARCHED			
Microrum documentation searched (describedion system followed by dissolication symbols) IPC 6 C07K				
Documentation searched other than minimum documentation to the extent that such documents are included in the lields searched				
Electronic data base consulted during the international search (theme of data base and, where practical, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Cetegory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
χ .	KLAMA K ET AL: "The abnormalities in the glycosylation of IgG" REUMATOLOGIA,	1-5, 10-14,20		
Y	vol. 34, no. 1, 1996, pages 26-30, XP002081302 see page 26, line 1 - page 27, last line	. 1–44		
X	LIFELY M R (REPRINT) ET AL: "Glycosylation and biological-activity of CAMPATH-H expressed in different cell-lines and grown under different culture conditions"	1-5, 10-14,20		
Y	GLYCOBIOLOGY, (DEC 1995) VOL. 5, NO. 8, PP. 813-822. ISSN: 0959-6658., XP002096118 see introduction and discussion	1-44		
	-/			
X Further documents era listed in the continuation of box C. Patent family members are listed in annex.				
**Special categories of claded documents: **A' document defining the general state of the art which is not class of the comment published after the international fitting date class of the comment published on or after the international fitting date. **C' comment of published on or after the international fitting date in the international published on or after the international fitting date. **C' comment of published references the international fitting date in the internatio				
Date of the actual completion of the international search Date of mailing of the international search report				
10 March 1999 0 7. 04. 99				
Name and meiling address of the ISA European Plaster Ottos, P.B. 5518 Patentisan 2 N. 2202 HY Plipsylle Tet. (43-170) 440-2010, Tr. 31 651 epon, Face (43-170) 440-2010 Muller—Thomalla, K				
Form PCT//SA/210 (second sheet) (July 1992)				

Interr 1al Application No PCT/US 98/21925

		PCT/US 98/21925
C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WRIGHT A ET AL: "Effect of altered CH2 -associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin Gl." JOURNAL OF EXPERIMENTAL MODICINE, (1994 SFP 1) 180 (3) 1087-96. JOURNAL CODE: 12V. ISSN: 0022-1007., XP000676306 United States	1-5, 10-14,20
Y	see abstract; page 1087, column 1, line 1 to page 1088, column 2, second paragraph; discussion	1-44
х	BOYD P N ET AL: "The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of CAMPATH-1H" MOLECULAR IMMOLOGY, vol. 32, MMOLMOLOGY, vol. 32, MMOLMOLOGY, col. 17/18, 1995, pages 1311-1318, XP000676340 cited in the application	1-5, 10-14,20
Y	see abstract and discussion	1-44
Y	UMANA P ET AL: "A mathematical model of N - linked glycoform biosynthesis" BIOTECHNOLOGY AND BIOTECHNOLOGY AND BIOTECHNOLOGY AND BIOTECHNOLOGY AND BIOTECHNOLOGY AND BIOTECHNOLOGY BIOTE	1-44
A	DMEK R A ET AL: "Glycobiology: 'the function of sugar in the Ig& molecule'." JOURNAL OF ANATOMY, (1995 OCT) 187 (PT 2) 279-92. JOURNAL COE: HBB ISSN: OCZ1-8782., YROD2096120 ENGLAND: United Kingdom see abstract, introduction; page 282, column 1, last paragraph to page 284, column 1, first paragraph;	
A	WEITZHANDLER M ET AL: "Analysis of carbohydrates on IgG preparations." JOURNAL OF PHARNACHITICAL SCIENCES, (1994 DEC) 83 (12) 1670-5. JOURNAL CODE: JO7. ISSN: 0022-3549., XP002096121 United States cited in the application see the whole document.	

Form PCTASA 210 Interinguation of second sheet) (July 195

Interr nat Application No PCT/US 98/21925

C.(Continu	(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
tegory *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.	
A	JEFFERSIS ET AL.: "6lycosylation of antibody molecules: Structural and functional significance." CHEMICAL JEMPMOLOGY, vol. 65, 1997, pages 111-128, XP002096122 cited in the application see the whole document		
Α .	WRIGHT ET AL.: "Effect of glycosylation on antibody funtion: implications for genetic engineering." IBIECH 1816. 1997, pages 26-32, XP004016809 cited in the application see the whole document		
A	WORMALD ET AL.: "Variations in oligosacharide-Protein interactions in immunoglobulin G determine the stde-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosacharides." BICHEMISTRY. vol 36, 1997, pages 1370-1380, XF002096123 cited in the application see the Whole document		
Х,Р	RAJU ET AL: "Biological significance and structural features of immunoglobulin glycoforms" BOOK OF ABSTRACTS. ACS NATIONAL MEETING, 29 April 1998, page COMPLETE 1 XP002081304 see abstract	1,2,35	
	Y.		

International application No. PCT/US 98/21925

Box 1	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
2. X	because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:	
	see FURTHER INFORMATION sheet PCT/ISA/210	
з. 🗌	Claims Nota.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Falls 6.4(a).	
Box #	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This in	ntemational Searching Authority found multiple inventions in this informational application, as follows:	
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.	
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which loss were paid, specifically claims Nos.:	
4.[No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the inversion first mentioned in the claims; it is covered by claims Nos.:	
Rem	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 218

Claims Nos.: claim 1 (partially)

The subject-matter of claim 1 which is defined mainly in terms of negative functional features is formulated in such an unclear manner that said claim could only be searched partially. In accordance with the definition of the invention given in the description , the subject-matter of claim 1 as searched has been interpreted as relating to a glycoprotein composition whereby at least one glycoprotein is a glycoprotein having at least one CHZ domain of the heavy chain immunoglobulin constant region, whereby said CHZ domain is substantially free of N-linked G1, G0 ir G-1 poliopsaccharide.